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CHAPTER I 
 Introduction 
5.8 The Myc oncogene 
The c-myc proto-oncogene encodes the c-Myc transcription factor, and was 
originally identified as the cellular homologue to the viral oncogene (v-
myc) of the avian myelocytomatosis retrovirus (Vennstrom et al., 1982). 
The c-myc gene is located on human chromosome 8q24. It was discovered 
soon after its identification that activated oncogenic c-myc was 
instrumental in the progression of the human Burkitt’s lymphoma, as a 
results of a translocation between chromosome 8 and one of the three 
chromosomes that contain antibody-encoding genes (Dalla Favera et al., 
1982). 
For 25 years, from its discovery, c-myc has been a pioneer in the oncogene 
field. Among the first cellular homolog of genes cloned from acute 
oncogenic viruses, it is also the first site of proviral integration at an 
oncogene, the first oncogene mapped to a chromosomal translocation 
breakpoint and the first oncogene found amplified in tumour cells.  
The c-myc gene is induced by a wealth of growth factors and is essential 
for most normal cells to proliferate. Following the deregulation of c-myc 
expression by translocation, gene amplification or aberrant signalling, c-
Myc becomes a potent oncoprotein that promotes unrestrained cell 
proliferation (Evan et al., 2001). Approximately 70% of human tumours 
have elevated c-myc expression, and suppression of c-myc expression can 
lead to regression of tumours (Felsher et al., 1999). 
 
1.2 Myc family members 
In mammals there are four related genes in the Myc family, c-myc, N-myc, 
L-myc and S-myc, all function as oncogenes in different tumors and have a 
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high degree of sequence conservation. A fifth gene, B-myc, encodes a 
protein that shows significant homology to the N-terminus, but lacks 
essential domains in the C-terminus, of the other Myc proteins, and its 
biology is poorly understood (Levens et al., 2003,; Eisenman, 2001).  
c-myc and N-myc are particularly well conserved and have equivalent 
oncogenic activities. Furthermore, their coding regions can substitute for 
each other in mouse development (Malynn et al., 2000). Myc proteins are 
also well conserved across species, which is reflected in the observation 
that the Drosophila myc gene, dmyc, can functionally substitute for 
mammalian c-myc.  
Since the viral oncogene (v-myc) of the avian myelocytomatosis retrovirus 
was a nuclear protein (Hann et al., 1983) several groups began to 
investigate whether Myc was a transcription factor by measuring the 
transcriptional response of individual genes to Myc expression (Dean et al., 
1987). Around the same time, the Myc C-terminus was found to contain a 
leucine zipper (LZ) and a helix-loop-helix (HLH) motif, both of which 
were previously found in sequence specific DNA-binding proteins (Murre 
et al., 1989; Landschulz et al., 1988). 
Myc dimerizes with the basic helix-loop-elix (bHLH)/Leu-zipper protein 
Myc-associated factor-X (Max) through a C-terminal HLH/Leu-zipper 
domain to facilitate DNA binding. 
The N-terminus of MYC protein contains a transactivation domain and a 
number of evolutionarily-conserved motifs known as MYC boxes (figure 
1). MYC boxes are well conserved across species (Cole and Cowling 
2008). In particular, MYC box II (MBII) is highly conserved and is the 
most important region of the transactivation domain. MBII is necessary for 
MYC binding to most cofactors, for the transactivation and repression of 
most MYC target genes and for the efficient execution of the biological 
effects of MYC. 
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Figure 1. The conserved regions of MYC. The three MYC proteins (MYC, MYCN and MYCL) are 
encoded by separate genes with distinct developmental regulation, but all three have been directly 
implicated in cancer. The N terminus of MYC contains the transactivation domain and the C-terminus 
contains the DNA-binding domain. The MYC boxes I, II, III and IV are indicated in red. The basic 
helixloop-helix/Leu zipper (bHLH/LZ) domain is indicated in green. MYC box II (MBII) has been shown 
to have a crucial role in most of the biological activities of MYC. The MBIV is not a component of the 
minimal DNA-binding domain but does influence DNA binding in vivo. 
 
The MBI and MBII were also found to be necessary for Myc to induce 
apoptosis and block differentiation. Two further Myc homology domains 
have been characterized. MBIII is necessary for cell transformation and 
deleting MBIII potentiates Myc-induced apoptosis (Herbst et al., 2005). 
MBIV is also necessary for full Myc transforming activity and apoptosis, 
and deleting MBIV potentiates Myc-induced G2 arrest (Cowling et al., 
2006). 
N-myc is another member of the Myc family prominently expressed in 
undifferentiated subsets of cells in the lung, heart, central and peripheral 
nervous system, kidney, visceral arches, limb buds, and eye (Zimmerman 
et al., 1986; Mugrauer et al., 1988; Downs et al., 1989; Hirvonen et al., 
1990; Hirning et al., 1991). 
There is not considerable sequence divergence among c-myc and N-myc, 
infact complementation experiments performed in Rat1 fibroblasts lacking 
Myc suggest that they are largely functionally redundant (Berns et al., 
2000; Nikiforov et al., 2000). Furthermore, mice in which the c-myc gene 
was replaced with the N-myc gene exhibited few developmental defects and 
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were viable (Malynn et al., 2000). Although they share a high degree of 
functional redundancy, N-myc and c-myc have strikingly distinct patterns of 
gene expression. Whereas c-myc, is expressed during embryonic 
development and in adult tissues, N-myc is expressed almost exclusively in 
embryonic tissues. It is also intriguing that N-myc and c-myc are expressed 
in highly complementary patterns during embryonic development (Hurlin 
et al., 1997).  
In most tissues and organs, N-myc is normally expressed in cell 
compartments comprised of progenitor populations. Collectively, N-myc 
maintains the cells in a proliferative and undifferentiated state. In this 
capacity, N-myc serves as an essential downstream target of various key 
signaling pathways (SHH, Wnt, TGF, and FGF pathways) to help 
coordinate morphogenesis. 
Among the members of the family, the N-myc oncogene is implicated in the 
pathogenesis of neural crest derived tumors including neuroblastoma, the 
most frequent solid malignancy in infants. Amplification of N-myc gene is 
the major negative prognostic marker in human neuroblastoma. 
 
1.3 Myc as transcription factor binds chromatin modifying 
complexes 
Myc is able to bind a partner protein, Max, through a basic-region/helix-
loop-helix/leucine-zipper (BR/HLH/LZ) domain (Blackwood et al., 1991). 
While Max can homodimerize and bind to DNA directly, Myc cannot 
homodimerize and must form an heterodimer with Max in order to bind the 
specific DNA sequence CACGTG (the E-box) (Blackwood et al., 1991). 
Max is a small, ubiquitously expressed protein that can bind to a whole 
collection of B-HLH-LZ proteins (Baudino et al., 2001). Transcription-
competent Myc/Max dimers are the active form of Myc in inducing cell-
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cycle progression, apoptosis and malignant transformation (Henriksson and 
Luscher, 1996; Amati and Land, 1994; Amati et al., 1993). 
Max factor can also form homodimers or heterodimers with several related 
proteins, known as Mad1, Mxi1 (also known as Mad2), Mad3, Mad4 and 
Mnt (also known as Rox), as shown by in vitro binding experiments (Ayer 
and Eisenman., 1993; Hurlin et al., 1997). The dimers all bind directly to 
the same DNA sequence (CACA/GTG), which is a subset of the general E-
box sequence (CANNTG) that is bound by all bHLH proteins (Blackwell et 
al., 1990). In vivo, Myc–Max complexes activate transcription through 
interactions with transcriptional coactivators (such as TRRAP and BAF53) 
and their associated histone acetyltransferases (HATs, e.g., GCN5) and/or 
ATPase/helicases (TIPs, e.g., TIP49) (McMahon et al., 1998, 2000 ; Dugan 
et al., 2002). This interactions are often predominant in proliferating cells 
(Figure 2A). Instead Mad–Max or Mnt–Max complexes are predominant 
in resting or differentiated cells (Ayer and Eisenman., 1993) where actively 
repress transcription through direct protein-protein interactions with the 
general transcriptional corepressors Sin3a/-3b (Ayer et al., 1995) with 
Sin3’s corepressors (e.g., N-Cor and the Ski/Sno proteins) and histone 
deacetylases (HDACs) (Alland et al., 1997; Heinzel et al., 1997). Histone 
deacetylation is currently thought to be the major mechanism of 
transcriptional silencing by the Mad proteins (Figure 2B). The Sin3-
intacting domain motif, when tethered to an HLH/LZ transcriptional factor, 
TFEB, that binds Myc DNA sites, is able to inhibit c-Myc-mediated 
cellular transformation (Harper et al., 1996).  
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Figure 2. MYC-MAX and MAD-MAX complexes regulate gene activation through chromatin 
remodelling.  A) MYC-MAX heterodimers binds to an E-box sequence (CACGTG) near the promoter 
of a c-MYC target gene. Co-activator TRRAP (transformation/transcription domain-associated protein), a 
component of a complex that contains histone acetyltransferase (HAT) activity, is then recruited to the 
MBII domain of c-MYC and acetylates (Ac) nucleosomal histone H4 at the E-box and adjacent regions. 
Nucleosomal acetylation alters chromatin structure, allowing accessibility of MYC-MAX transcriptional-
activator complexes to target DNA, resulting in expression of the target gene. B) Induction of MAD 
during terminal differentiation results in the MAD-MAX heterodimer binding to an E-box of a c-MYC 
target gene. Corepressor SIN3 and histone deacetylases (HDACs) are then recruited to MAD, resulting in 
local nucleosomal histone deacetylation and repression of target-gene expression. 
 
The nuclear cofactor TRRAP (transactivation/transformation-domain 
associated protein), was purified by affinity chromatography using the c-
Myc N-terminal transactivation domain (McMahon et al. 1998). TRRAP is 
a 3,830-amino-acid protein with limited homology to the phosphoinositide 
(PI)-3 kinase/ATM family, although TRRAP lacks the kinase catalytic 
residues present in other members of the family (McMahon et al. 1998). 
Myc was found to bind directly to an internal domain of TRRAP. Deletions 
in the Myc MBI and MBII regions which inhibit transformation also inhibit 
TRRAP binding (McMahon et al. 1998; Nikiforov et al. 2002). The 
identification of TRRAP as an essential cofactor provided an important 
mechanistic insight into the function of the Myc N-terminal domain when 
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TRRAP was found to be part of the SAGA complex (Grant et al. 1998a; 
Saleh et al. 1998; Vassilev et al. 1998). SAGA 
(SPT/ADA/GCN5/acetyltransferase) is a 1.8-Mda complex containing 
approximately 20 proteins, which has been implicated in transcriptional 
regulation, primarily through genetic screens in yeast (Grant et al. 1997).  
Among the many proteins contained in SAGA, the only one with a clearly 
defined biochemical function is the histone acetyltransferase GCN5 
(Georgakopoulos and Thireos 1992; Marcus et al. 1994; Wang et al. 1997). 
Histone acetylation by transcription cofactors has frequently been 
associated with gene activation (Grant et al. 1998b), making this an 
attractive mechanism for Myc-mediated transactivation (Figure 3). 
TRRAP is also found in a complex with the H2A/H4 histone acetylase 
TIP60 (Ikura et al. 2000). 
Overexpression of a catalytically inactive TIP60 HAT delays the induction 
of H4 acetylation of target genes by Myc and also reduces Myc binding to 
chromatin, although no reduction in target gene induction was found. The 
subunits in these TRRAP complexes largely overlap those in a complex 
containing the Swi/Snf-related p400 protein in mammalian cells. Myc 
binds to this complex through TRRAP, but the consequences of Myc 
binding remain unclear since the p400/TRRAP complex is reported to lack 
histone acetyltransferase activity (Fuchs et al., 2001). 
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Figure 3. Model for Myc recruitment of histone acetyltransferases that open chromatin through 
acetylation of  nucleosome. The Myc protein recruits several complexes that can promote localized 
modification and remodeling of chromatin. These complexes may alter the acetylation around Myc target 
genes or perturb chromatin in some other undefined way. 
 
Another set of cofactors recruited by Myc are evolutionarily conserved 
proteins called TIP49 and TIP48, which contain ATPase motifs (Wood et 
al. 2000). These proteins are found as part of the TRRAP : TIP60 HAT 
complex in mammalian cells (Ikura et al. 2000), but some mutations in 
Myc retain TIP49/48 binding while losing TRRAP binding, suggesting that 
these proteins may interact with Myc independently (Wood et al. 2000). 
They are not components of the analogous H4 histone acetyltransferase 
complex in yeast (Allard et al. 1999), although they are found in other yeast 
chromatin remodeling complexes (Shen et al. 2000). 
Another evidence that link Myc to chromatin remodeling is its interaction 
with SNF5 (also known as INI1/BAF47), a subunit of the human Swi/Snf 
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complex. Co-expression of a dominant-negative mutant of Brg1, the 
catalytic subunit of Swi/Snf, suppressed reporter gene activation by Myc in 
a transient transfection assay (Cheng et al., 1999), suggesting a role for 
Swi/Snf in transcriptional activation by Myc.  
Other acetyltransferase activity factors that interacts with Myc (and many 
other transcription factors) are p300 and CBP (Figure 3). Cotransfection of 
CBP with Myc stimulates transactivation and CBP is weakly recruited to 
Myc target genes in vivo. One of the substrates for CBP/p300 is Myc itself, 
with several distinct sites acetylated in transient cotransfection assays 
(Vervoorts et al., 2003; Faiola et al., 2005).  
1.4 Myc-induced transactivation is also regulated at the level of 
transcriptional elongation 
A recent global genome analysis reports the presence of paused RNA pol II 
at specific promoters, including those of heat shock and MYC genes 
(Saunders 2006). This finding suggests that regulation of transcription also 
occurs at the level of transcriptional elongation and not just at 
transcriptional initiation. RNA pol II undergoes a cycle of phosphorylation 
and dephosphorylation during transcription and, with its C-terminal domain 
(CTD) in a hypophosphorylated form, RNA pol II is recruited to promoters. 
Phosphorylation of the CTD occurs during transcription initiation and 
elongation, whereas the CTD must be dephosphorylated to allow RNA pol 
II to be recycled for another round of transcription (Figure 4). RNA pol II 
has been found to pause on most promoters after transcribing 
approximately 20–40 bases. Specific signals and cofactors then stimulate 
transcriptional elongation and further RNA pol II phosphorylation (Price 
2008). 
This model fits well with the earlier finding that MYC does not induce 
transcription of the target gene CAD (carbamoylphosphate synthetase-2, 
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aspartate transcarbamylase, dihydroorotase) by driving RNA pol II 
recruitment, but rather stimulates the release of paused RNA pol II from the 
promoter and stimulates subsequent transcriptional elongation (Figure 5) 
(Eberhardy and Farnham 2001). Thus, some Myc target genes are TRRAP 
and/or histone acetylation independent.  
Investigation into the HAT independent activation of Myc target genes 
revealed that RNA pol II is engaged but stalled at the promoters of some 
Myc target genes in the absence of Myc (Eberhardy and Farnham 2002). In 
the case of the CAD gene, Myc binding must regulate RNA pol II promoter 
clearance. Stimulation of RNApol II promoter clearance and efficient 
transcription elongation is associated with the RNA pol II kinases, TFIIH 
and positive transcription elongation factor b (P-TEFb). GST-Myc was 
found to bind to both subunits of P-TEFb, cyclin T1 and CDK9. In a 
separate study, MycER stimulated the recruitment of mediator, TFII-H, and 
P-TEFb to the cyclin D2 promoter (Bouchard 2004).  
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Figure 4: Transcription elongation – The Pol II CTD phosphorylation cycle .After RNAPII has been 
recruited into a pre-initiation complex, the CTD repeat is phosphorylated on Ser 5 by the CDK-7 subunit 
of the GTF TFIIH. This phosphorylation is required for Pol II to transcribe beyond the immediate 
promoter region (clearance), and for recruitment of the mRNA capping enzyme. Subsequently, 
phosphorylation of CTD Ser 2 by CDK-9 facilitates elongation and is required for mRNA termination, 
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cleavage, and processing . CDK-9 is a subunit of the GTF P-TEFb (positive transcription elongation 
factor b)  
 
 
 
Figure 5. MYC recruits basal transcription factors and promotes the clearance of promoters 
through RNA polymerase (pol) II. RNA pol II is frequently paused on promoters after phosphorylation 
of Ser5 on the RNA pol II C-terminal domain (CTD) and synthesis of a short (20–40 base) segment of 
mRNA28. The MYC protein can promote a paused RNA pol to continue transcription of the mRNA by 
recruiting the P-TEFb (positive transcription-elongation factor-b) complex, which phosphorylates the 
CTD on Ser2 and promotes transcriptional elongation. 
1.5 The P-TEFb complex 
The positive transcription elongation factor b (P-TEFb) is a cyclin-
dependent kinase that controls the elongation phase of transcription by 
RNA pol II (Peterlin and Price 2006). The RNA pol II C-terminal domain 
(CTD) is hypophosphorylated when initially recruited to genes, and 
undergoes sequential phosphorylation at Ser5 during promoter clearance 
and at Ser2 by P-TEFb at start of elongation (Price 2000). 
Recently it has been shown that P-TEFb influences multiple steps in gene 
expression, from transcription elongation and co-transcriptional control of 
mRNA processing and export through the CTD, to mRNA translation in 
the cytoplasm. Therefore P-TEFb has been defined a multi-tasking 
complex (Bres et al., 2008).   
P-TEFb complex exists in the cells in two forms in dynamic equilibrium 
between them. The catalitically active form (small comlex) is a 
heterodimeric complex and comprises two subunit, cyclin-dependent 
kinase-9 (CDK9) and Cyclin T1, T2 or K. The other half of P-TEFb exists 
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in a calitically inactive form (Nguyen et al., 2001; Yang et al., 2001, 
Michels et al., 2003 ), the large complex, that comprises 7SK small nuclear 
RNA (7SKsnRNA) and HEXIM1 (Michels et al., 2003; Yik et al., 2003; 
Chen et al., 2004; Nguyen et al., 2001; Yang et al., 2001) or HEXIM2 
protein (Blazek et al., 2005). It has shown that active and inactive P-TEFb 
complexes are in rapid equilibrium, either a transcriptional arrest, 
genotoxic insults and UV or RNase treatments, triggers dissociation of 7SK 
and HEXIM1 from CDK9/Cyclin T1 resulting in a subsequent 
accumulation of kinase active P-TEFb complex (Figure 6). 
High Kinase Activity Low Kinase Activity
I II
• Stalled transcription
• UV
• Genotoxic insults
• RNase
CDK9
Cyclin T1
CDK9
Cyclin T1
7SKsnRNA
HEXIM1
 
 
Figure 6: Active and inactive complexes of P-TEFb. P-TEFb is regulated by its reversible association 
with HEXIM1 and 7SK RNA. When P-TEFb is in this RNA-protein complex , its kinase activity is 
inhibited.  
 
Notably, the core active P-TEFb complex, is likely also associated with the 
positive regulator bromodomain Brd4 (Jang et al., 2005; Yang et al., 2005). 
In fact, besides 7SK and HEXIM1, Brd4 has recently been identified as a 
major factor associated with CycT1/CDK9 heterodimer (Jang et al., 2005). 
Brd4 is a bromodomain protein  that binds highly acetylated chromatin (Wu 
et al., 2007) and interacts with mediator complex. Brd4 may therefore link 
P-TEFb recruitment with histone acetylation at induced genes. 
Many studies has shown that P-TEFb is not only essential for the 
expression of most cellular protein-encoding genes, but also it is 
indispensable for the replication of human immunodeficiency virus type 1 
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(HIV-1) (Jones et al., 1997; Cullen et al., 1998). Transcription of HIV-1 
proviral DNA by RNAPII is controlled primarily at the level of elongation 
by the viral Tat protein (Barboric and Peterlin 2005). Tat is a protein 
encoded by HIV-1, transcribed from multiply spliced viral RNA molecules 
expressed at early stages of viral gene expression. It is composed of the two 
exons of the viral Tat gene and encodes a protein of approximately 101 
amino acids and in the late stage of the infection cycle, a carboxy-
terminally truncated, encoded for Tat protein of 72 aminoacids also 
sufficient to transactivate the HIV-1 promoter.  
Cyclin T1 was originally identified as a direct binding partner of the HIV-1 
Tat protein in HeLa nuclear extracts, and Tat and Cyc T1 cooperate to 
recruit P-TEFb to the viral 5’ TAR RNA (Price 2000; Saunders et al., 
2006). An equally conserved arginine-rich motif is essential for direct 
contact of Tat with TAR RNA. Tat and cyclin T1 bind TAR RNA 
cooperatively and induce phosphorylation of the C-terminal domain of 
RNA pol II by CDK9 (Figure 7). 
 
Figure 7. HIV-1 Tat transactivation involves the human P-TEFb complex. Tat interacts with cellular 
proteins as well as either a highly structured RNA element, transactivation-responsive TAR RNA, which 
is located at the 5’ end of nascent viral transcripts. Tat binds CyclinT1 by a conserved domain cysteine-
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rich region, which is part of trans-activating domain. An equally cis-region is essential for direct contact 
of Tat with TAR RNA cooperatively and induces phosphorylation of the C-terminal domain of RNAPII 
by CDK9. Neither CycT1 nor the P-TEFb complex binds TAR RNA in the absence of Tat, signifying that 
binding to RNA is highly cooperative for both Tat and P-TEFb. Since most of the P-TEFb are sequestered 
in the catalytically inactive and active complexes in cells, Tat could in principle modulate their 
configurations to increase the pool of P-TEFb for efficient HIV-1 transcription. 
1.6 c-Myc regulation and turnover 
c-myc activity is normally tightly controlled, at transcription level, by 
external signals including growth factors, mitogens and β-catenin. 
In its physiological role, c-myc is broadly expressed during embryogenesis 
and in tissue compartments of the adult that possess high proliferative 
capacity (such as skin epidermis and gut). Its expression strongly correlates 
with cell proliferation. In quiescent cells in vitro, c-myc expression is 
virtually undetectable. However, after mitogenic or serum stimulation, c-
Myc mRNA and protein are rapidly induced and cells enter the G1 phase of 
the cell cycle. Thereafter, the mRNA and protein decline to low, but 
detectable, steady-state levels in proliferating cells. If serum or growth 
factors are removed, c-Myc levels decline to undetectable levels and cells 
arrest. Temporal regulation of c-Myc protein accumulation is essential for 
normal cell proliferation.  
c-Myc protein is stabilized after activation of Ras, allowing it to 
accumulate to high levels (Sears et al., 1999). Ras promotes stability of c-
Myc through at least two effector pathways: the Raf–MEK–ERK kinase 
cascade, and the phosphatidylinositol-3-OH kinase (PI(3)K)–Akt pathway 
that inhibits glycogen synthase kinase-3β (GSK-3β) (Figure 8). The ERK 
and GSK-3β kinases phosphorylate two sites near the amino terminus of c-
Myc that are highly conserved in all mammalian c-Myc isoforms. These 
phosphorylation sites, Thr 58 and Ser 62, exert opposing control on c-Myc 
degradation through the ubiquitin- proteasome pathway (Sears et al., 2000).  
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Thus, after a growth stimulatory signal, c-Myc gene transcription is 
increased and newly synthesized c-Myc protein is phosphorylated on Ser 
62, via the Raf–MEK–ERK pathway, resulting in its stabilization. 
Phosphorylation at Ser 62 is also required for the subsequent 
phosphorylation of c-Myc at Thr 58 by GSK-3β, which is associated with 
c-Myc degradation (Sears et al., 2000; Pulverer et al 1994). During early 
G1 phase, however, GSK-3β  activity is regulated by Ras-mediated 
activation of the PI(3)K/Akt pathway (which phosphorylates and inhibits 
GSK-3β), facilitating stabilization of c-Myc. Later in G1 phase, Ras 
activity declines after cessation of the growth stimulus, PI(3)K and Akt 
activities also decline, resulting in reactivation of GSK-3β and 
phosphorylation of c-Myc on Thr 58 which is important for c-Myc 
turnover. Phosphorylation of Thr 58 is important for recognition of c-Myc 
by the Pin1 prolyl isomerase. Pin1 facilitates c-Myc dephosphorylation at 
Ser 62 by PP2A, which then promotes c-Myc turnover by the ubiquitin-
proteasome pathway through E3 ligase SCFFBW7 that recognizes Phospho-
Thr 58. Thus, the mechanism that stabilizes and amplifies c-Myc 
accumulation, c-Myc phosphorylation at Ser 62, also triggers the 
subsequent phosphorylation at Thr 58 and the series of events that 
culminate in c-Myc degradation.  
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Figure 8. ‘‘Myc modification cycle’’ regulating protein turnover and activity. A series of 
posttranslational modifications in MBI regulates Myc’s interactions with ubiquitin ligases and may 
impact its transcriptional activities.  
 
Recently it has been demonstrated (Bonetti et al., 2008) that 
Nucleophosmin, NPM/B23 protein regulate c-Myc turnover through 
Fbw7, a nucleolar ubiquitin ligase previously implicated in the 
ubiquitination/degradation of  c-Myc ( Yada et al., 2004 ). 
NPM is a nucleolar protein that shuttles continuously between the nucleus 
and the cytoplasm (Grisendi et al., 2006 ). NPM has been proposed to 
regulate ribosomal RNA transcription/processing and the transport of 
preribosomal particles to the cytoplasm and in vivo interacts with many 
growth regulators, including the tumor suppressors p53 and ARF, and the 
HDM2 (Mdm2 in mouse) oncogene. 
This protein is well known to regulate ARF tumor suppressor. In NPM-null 
cells, ARF loses its physiological localization in the nucleolus and becomes 
unstable, which suggests that NPM is critical for the proper localization 
and stability of ARF (Colombo et al., 2005). Notably, this function of NPM 
is lost for AML associated NPM alleles (NPM-mut), which compete with 
wild type NPM for ARF binding but target ARF to the cytoplasm, where it 
becomes more susceptible to degradation.  
In the absence of NPM or in the presence of NPM-mut, cells express 
increased levels of the c-Myc proto-oncogene. NPM interacts with FBW7 
and in the absence of NPM, FBW7 loses its nucleolar localization and is 
rapidly degraded by the proteasome. As a consequence, ubiquitination of c-
Myc is defective and the protein is stabilized. NPM-mut maintains the 
property of interacting with FBW7 but delocalizes it to the cytoplasm, 
where it is degraded, thus leading to accumulation of c-Myc and increased 
c-Myc signaling (Figure 9). Thus, mutations of NPM seem to 
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simultaneously dampen a tumor-suppressor pathway (p53 – ARF) and 
enhance an oncogenic c-Myc pathway. 
 
Figure 9. Mutated NMP attenuates an oncosuppressor pathway and enhances an oncogenic one. 
Normal cell: NPM is mainly localized in the nucleolus and is required for nucleolar accumulation and 
stability of FBW7γ and ARF. This is relevant for the control of MYC turnover and provides an active 
pool of ARF ready to inactivate the HDM2-mediated p53 degradation in response to cellular stress. AML 
blast: NPM-mut is mainly localized to the cytoplasm and causes cytoplasmic delocalization and 
degradation of ARF and FBW7 γ. As a consequence, HDM2 can induce ubiquitination/degradation of 
p53, and MYC accumulates and activates its target genes. 
1.7 Myc regulates the RNA polymerase I and RNA polymerase 
III dependent transcription. 
The most distinctive signatures of target genes downstream of Myc are the 
genes involved in ribosome and protein biogenesis (Schlosser et al., 2003; 
Boon et al., 2001). Regulation of the protein synthesis machinery is a 
critical component of growth regulation since a cell must double its protein 
mass before division. An important recent finding is that Myc stimulates 
rDNA transcription in both mammals and Drosophila (Grewal et al., 2005 – 
Arabi et al., 2005). Elevated Myc expression increases rDNA transcription 
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and nucleolar size in both mammalian cells and Drosophila embryos. Myc 
is able to bind to the rDNA repeats in mammalian cells, but not in 
Drosophila, although the sites of interactions are still controversial. 
Induction of rDNA transcription has been found to be dependent on MBII, 
and binding was accompanied by recruitment of TRRAP and histone 
acetyltransferases as well as RNA polI transcription factors (Grandori et 
al., 2005). If Myc stimulates rDNA transcription, the ribosome content per 
cell should also increase, which was demonstrated directly in two studies 
(Grewal et al., 2005; Grandori et al., 2005). These observations have a 
profound implication for interpreting the Myc target gene response.  
For protein synthesis, the translation apparatus needs tRNA and 5S RNA in 
addition to ribosomes and translation cofactors. Therefore, it is consistent 
with Myc’s prominent influence on translation, that it also enhances RNA 
polymerase III activity (Gomez-Roman et al., 2003). RNA Pol III 
transcribes tRNA and 5S RNA genes using a distinct set of cofactors than 
those used by RNA Pol I and RNA Pol II. Overexpression of Myc or 
activation of Myc-ER by tamoxifen leads to a rapid induction of Pol III 
activity and binding of Myc to Pol III-transcribed genes, even though these 
genes do not have consensus Myc/Max binding sites. The mechanism of 
RNA Pol III activation remains unclear, but the Myc transactivation 
domain (amino acids 1–110 or 106–143) is required. By using pull down 
assays, it has been found that interaction between the Myc transactivation 
domain and the basal RNA Pol III cofactor TFIIIB occurs. Determining 
how Myc binding to TFIIIB and RNA Pol III can stimulate activity will 
require further investigation. 
1.8 Emerging novel function of Myc:  regulation of translation 
A number of experimental findings have suggested that Myc might have 
biologically significant, transcription-independent functions. 
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First, Myc biological activity can be uncoupled from the regulation of 
transcription by mutant analysis. Mutations near the DNA-binding domain 
can reduce the DNA-binding activity of Myc with no effect on Myc 
dependent cell proliferation and rat embryo fibroblast cell transformation 
(Cowling et al., 2006). Second, Myc mutants that cannot dimerize with 
MAX or lack DNA-binding activity can promote cell proliferation 
(Cowling and Cole 2007). These findings imply that inherent DNA binding 
and transcriptional activation are not required for every biological activity 
of Myc.   
Recently it has been found that Myc can increase protein abundance by 
directly regulating the translation of individual mRNAs. This novel Myc 
mechanism came from the observation that the protein levels of several 
cyclin and cyclin-dependent kinases (CDKs), which are required for cell-
cycle progression and transcription, abundantly increased in response to 
Myc expression without any change in their mRNA levels or in their 
requirement for the DNA-binding domain of Myc (Cowling and Cole 
2007). Conversely, reducing the level of Myc in normal fibroblasts by 
small interfering RNA led to a suppression of cyclin and CDK protein 
levels without causing a suppression of mRNA levels, demonstrating that 
endogenous Myc protein has an activity that is comparable to the Myc 
mutants that lack direct DNA-binding activity. 
Myc was found to increase the translation of specific mRNAs by promoting 
the methylation of the 5′ mRNA guanine or ‘cap’ (Cowling and Cole 
2007), which is an essential step for protein-coding gene expression. Genes 
that are subject to Myc-dependent cap methylation, for example, cyclin T1 
and CDK9, represent a novel set of Myc responsive genes.  
During the early stages of transcription mRNA is capped and methylated. 
Cap methylation is necessary for the binding of translation factors to the 
mRNA and thus is required for translation (Bentley, 2005; Shuman, 2002). 
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Both capping enzyme and RNA methyl transferase are recruited to mRNA 
after transcription initiation by binding specifically to the RNA pol II CTD, 
which has been phosphorylated on Ser5 by the kinase TFIIH and on Ser2 
by P-TEFb complex.  
Myc can stimulate the methylation of specific mRNA modulating the levels 
of RNA pol II phosphorylation by elongation factors recruitment (Figure 
10). 
 
 
Figure 10. Mechanism of MYC-induced mRNA cap methylation. MYC promotes recruitment of the 
transcription factor TFIIH kinase to promoters and RNA polymerase (pol) II phosphorylation. Increased 
RNA pol II phosphorylation increases cap RNA methyltransferase (RNMT) recruitment and/or activity, 
which correlates with MYC-dependent mRNA cap methylation. At direct MYC target genes (left), TFIIH 
enhances the recruitment or activity of the cap RNMT to increase the fraction of cap methylated mRNA. 
At other promoters (right), MYC stimulates mRNA cap methylation through TFIIH stimulation by the 
MYC transactivation domain and through the subsequent recruitment or activation of RNMT by C-
terminal domain phosphorylation. In doing so, MYC functions as a transcription-independent factor. 
Activation of direct targets is MYC-associated factor-X (MAX)-dependent (left), whereas activation of 
transcription-independent targets is MAX-independent (right). 
 
1.9 Emerging novel function of Myc: control of DNA replication 
In DNA replication the genome must be faithfully replicated at each cell 
cycle and the chromosomes must be segregated to the daughter cells. 
Disruption of any step in this process, such as a stalled replication fork or 
DNA damage incurred during S phase, activates a checkpoint that halts the 
cell cycle until the lesion can be repaired (Machida et al., 2005).Failure to 
correct this damage leads to a mutation and/or genomic instability. 
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A recent study describes a direct, non-transcriptional role for Myc in the 
initiation of DNA replication (Dominguez-Sola et al., 2007) Myc was 
found to bind to numerous components of the pre-replicative 
complex, including MCM proteins, ORC2, CDC6 and CDT1, and localize 
to early sites of DNA replication. These observations suggested that Myc 
might directly control the initiation of S phase and that Myc effects on 
genomic instability might not depend on the transcriptional induction of S-
phase-promoting genes. 
Levels of Myc protein seem to govern the number of active replication 
origins in both Xenopus and mammalian cells, suggesting that Myc 
functions to control origin selection.  
Because this activity is dependent on the integrity of both the N-terminal 
and C-terminal domains of Myc, it suggests that Myc directly binds to 
DNA to recruit factors that govern the firing of replication origins. 
1.10 Antagonism of Myc functions by p14ARF   
 
Myc was the first oncogene recognized to activate ARF (Alternative 
reading frame) gene expression (Zindy et al., 1998). The ARF tumour 
suppressor is transcriptionally induced in response to the overexpression or 
mutational activation of growth-promoting genes, including MYC and 
RAS, and responds in turn by inhibiting the p53-specific ubiquitin ligases 
MDM2 (Korgaonkar et al., 2002) and ARF-BP1 (Chen et al., 2005), 
leading to the initiation of a p53-dependent cell growth arrest and apoptosis 
program. In order to induce cell-cycle arrest ARF functionally antagonizes 
gene expression governed by transcription factors such as E2F and MYC, 
the activities of which are required for cell-cycle progression.  
However, several groups of investigators have argued that ARF functions 
independently of p53 in physically binding to E2F1 and MYC and 
attenuating their transcriptional activity (Eymin et al., 2001; Qi et al., 2004; 
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Datta et al., 2004). As for E2F1, the interactions between ARF and MYC 
highlight a p53-independent negative feedback mechanism (Figure 11). In 
some cell lines in which MYC expression was enforced, MYC binding 
relocalized ARF from the nucleolus to the nucleoplasm, whereas in other 
cell types ARF was found to import MYC into nucleoli (Qi et al., 2004; 
Datta et al., 2004). However, more striking were observations that p19ARF 
could associate with MYC on chromatin, antagonizing the transactivation 
of selected MYC target genes without impairing its transrepression of 
others (Gregory et al., 2005). The dampening effects of ARF on MYC-
regulated transcription did not result from interference with MYC binding 
to its heterodimerization partner MAX, did not depend on MDM2 and p53 
and, in Trp53-null cells, preceded the inhibition of S-phase progression. 
ARF does not interfere with apoptosis induction by Myc, suggesting a role 
of ARF as a checkpoint for Myc-induced oncogenesis. Similarly, ARF 
antagonizes the activities of other transcription factors, including the 
forkhead box (Fox) family member FOXM1B, B-cell lymphoma 6 (BCL6), 
p63 and HIF-1α (Suzuki et al., 2005; Calabro et al., 2004; Fatyol et al., 
2001). 
 
 
Figure 11. Functional interactions of MYC, ARF and p53.  MYC is one of several ongogenes that can 
induce ARF expression when overexpressed, which in turn antagonizes the function of MDM2 to 
stabilize p53. The p53 protein not only feeds back to induce the transcription of MDM2 but also 
negatively regulates ARF and endogenous MYC expression through as yet ill-defined mechanisms. The 
ARF protein reportedly binds directly to MYC to inhibit its transactivation functions selectively. 
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1.11 ARF (Alternative Reading Frame) tumour suppressor 
The INK4a–ARF locus (CDKN2A in humans) encodes two intimately 
linked but distinct tumor-suppressor proteins, p16INK4a and p14ARF 
(p19ARF in the mouse), that indirectly govern the activities of the 
retinoblastoma protein (RB) and the p53 transcription factor, respectively. 
These four proteins comprise part of a complex signaling network that 
regulates checkpoint responses to oncogenic stress by halting cell division 
and/or eliminating cells that have sustained irreparable damage (Lowe et al 
2003). The intercalation of an additional exon (designated exon 1β) 
between the INK4a and INK4b genes enables  the production of an 
alternatively spliced mRNA that also incorporates sequences encoded by 
exons 2 and 3 of INK4a (Figure 12). Unexpectedly, this transcript was 
found to specify an entirely unrelated protein, the exon-2-derived segment 
of which is translated in an alternative reading frame (ARF) (Quelle et al., 
1995). 
 
Figure 12. The INK4b–ARF–INK4a locus includes three tumour-suppressor genes in close 
proximity to one another. Numbered exons (E) are indicated by coloured rectangles and the promoters 
of the genes are designated by arrows. Both INK4a (green) and INK4b (orange) encode inhibitors 
(p16INK4a and p15INK4b) of the cyclin D-dependent kinases CDK4 and CDK6. The two INK4 genes 
flank ARF exon 1β, the encoded RNA of which is spliced (indicated by connecting lines below the linear 
schematic) to the exon-2- and  exon-3-encoded segments of  the INK4a gene (ARF-encoding exons in 
blue). The initiator codons in the ARF and INK4a mRNAs open alternative reading frames in INK4a 
exon 2 (from which the ARF gene got its name). 
 
The ARF protein has an unusual amino-acid composition, being highly 
basic (pI>12, despite a paucity of lysine residues); from all the evidences 
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present in the literature it can be hypothesized that p14ARF is probably 
unstructured unless bound to other targets and highly promiscuous in its 
binding (Sherr 2006).  
During the last years many efforts have been attempted in search ARF 
partners. The ARF interactors ‘‘harem’’ consists of something like 30 
different proteins involved in various cellular activities (Figure 13): 
proteins involved in transcriptional control, such as E2Fs, DP1, c-Myc, 
p63, Hif1a, Foxm1b, nucleolar proteins such as nucleolin/C23 and 
nucleophosmin (NPM/B23), viral proteins such as HIV-1Tat, proteins 
involved in copper metabolism like COMMD1, proteins involved in 
chromosomal stability and/or chromatin structure such as Topoisomerase I, 
Tip60, and WRN helicase, ubiquitin ligases like Ubc9 (the E2 ligase 
required for sumoylation), MDM2 and ARF-BP1/Mule, (E3-ubiquitin 
ligases). Although the mechanisms by which ARF affects the activity of its 
partners are still unclear, the functional consequence is, quite invariably, 
inactivation. 
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Figure 13.  A schematic view of the ‘‘ARF harem’’. Orange is for partners whose activity is blocked by 
ARF. Red is for partners that are induced to proteasome and ubiquitin-dependent degradation by ARF. 
Pink is for partners that are induced to proteasome and ubiquitin-independent degradation by ARF. Green 
is for partners whose activity or stability are positively regulated by ARF. Blue is for partners that 
regulate ARF protein turnover. A second black circle indicate nucleolar sequestration. 
 
The discovery of multiple ARF interactors and the observation that, aside 
oncogenic stimuli, also viral, genotoxic, hypoxic and oxidative stresses 
activate an ARF-dependent response, suggest that ARF could exert a wider 
role to protect the cell (Eymin et al., 2006; Fatyol et al., 2001; Garcia et al., 
2006; Menendez et al., 2003). 
It has recently been shown that the p19ARF mRNA can produce a short 
isoform of the ARF protein by internal initiation of translation at 
methionine 45 (Reef et al., 2006 and Sherr 2006). This isoform, dubbed 
short mitochondrial ARF or smARF, lacks the ARF NH2-terminal region 
that contains the MDM2 and ARF-BP1 binding domains required for 
ubiquitin ligase inhibition and, consequently, for p53-dependent ARF 
function. smARF also lacks the p19ARF nucleolar localization signal and 
is therefore excluded from the nucleolar compartment, localizing to 
mitochondria instead. This isoform induces cell death by autophagy, a 
cellular process associated with type II programmed cell death and 
characterized by the formation of cytosolic double-membrane vesicles, 
called autophagosomes, that engulf cellular content and fuse with 
lysosomes to digest it (Levine et al., 2004). Autophagy has been implicated 
in tumor suppression (Jin 2005) via full-length ARF in both p53-dependent 
and p53-independent manners, depending on cellular context (Abida and 
Gu 2008). 
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1.12 ARF exerts p53-dependent or p53-independent tumour 
suppressor functions 
ARF protein is a potent tumour suppressor that blocks cell-cycle 
progression by directly binding to, and interfering with, the p53 negative-
regulator MDM2 (HDM2 in human), thereby stabilizing and activating p53 
(Kamijo et al., 1997; Stott et al., 1998). In turn, by antagonizing the E3 
ubiquitin ligase activity of MDM2, ARF stabilizes p53 and increases its 
transcriptional activity (Figure 14). The proto-oncoprotein HDM2 also 
interacts with HIV-1 Tat protein and mediates its ubiquitination in vivo and 
in vitro (Bres et al., 2003). HDM2 is a positive regulator of Tat-mediated 
transactivation, indicating that the transcriptional properties of Tat are 
stimulated by ubiquitination. 
The most accepted view was that the tumor-suppressor functions of ARF 
was mediated through p53. 
 
Figure 14. The ARF-MDM2-p53 pathway.  Once expressed,  the ARF protein interferes with the 
activity of MDM2, leading to p53 stabilization and triggering a complex p53-dependent transcriptional  
programme mediated by hundreds of target genes MDM2 is not only a negative regulator of p53-
dependent transcription and turnover, but is also a canonical p53-activated gene that has a key role in 
negative-feedback regulation of the p53 response. The activation of p53 classically occurs in response to 
many other cellular stresses that produce DNA damage. DNA-damage responses activate the kinase 
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mutated in the ataxia telangectasia syndrome (ATM) and/or the ATM and RAD3-related kinase (ATR). 
These kinases phosphorylate p53 directly and also indirectly through the agency of the CHK kinases. 
These phosphorylations have an important role in increasing the transcriptional activity of p53. Target  
genes induced by p53 can generate different biological outcomes depending on the tissue type and 
convergence of different activating signals. ARF induction primarily tends to trigger cell-cycle arrest, but 
oncogene-induced signals conveyed through collateral pathways (not shown) can shift the response from 
growth arrest to apoptosis. 
 
Despite this neat paradigm, there is evidence to suggest that ARF might 
have additional tumour-suppressor activities.  
The reintroduction of p19ARF into primary Trp53-null or TKO murine 
embryonic fibroblasts (MEFs) can arrest their proliferation, albeit much 
less efficiently than in cells that retain the expression of MDM2 and p53 
(Weber et al., 2000 and Carnero et al., 2000). 
Roles for p14ARF in triggering the growth arrest or apoptosis of p53-
deficient human tumour cell lines in culture and in inhibiting their growth 
as xenografts in nude mice have also been described (Eymin et al., 2001 
and Eymin et al., 2003).  
These observations raised the idea that ARF has an MDM2- and p53-
independent role as a tumour suppressor. 
 
1.13 ARF NPM/B23 interaction 
On induction, the ARF protein accumulates within the nucleolus, an 
intranuclear organelle primarily concerned with ribosome biosynthesis. 
Here, the ARF protein associates in high-molecular-mass complexes with 
nucleophosmin (NPM, also known as B23, numatrin or NO38) (Itahana et 
al., 2003 and Korgaonkar 2005), an abundant nucleolar phosphoprotein of 
37 kDa. Although most NPM resides within the nucleolus, the protein 
contains a nuclear export signal (NES) and shuttles between the nucleus 
and cytoplasm. NPM has been implicated in diverse cellular processes, 
including ribosome biogenesis, centrosome duplication, DNA-damage 
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responses, transcription and nucleosome remodelling (Grisendi et al., 
2006).  
The complexes including ARF and NPM are much more abundant than 
ARF–MDM2 complexes. ARF is stable when expressed within the 
nucleolus, but turns over more rapidly in the nucleoplasm. ARF proteins 
are polyubiquitylated at their free (non-acetylated) N-termini and are 
degraded by the proteasome (Kuo et al., 2004). In response to increased 
levels of NPM, the turnover of p19ARF is retarded, therefore, the ARF 
protein assumes a stable structure when bound to NPM. 
NPM is also responsible for ARF nucleolar compartmentalization. Recently 
it has been found the identification of leukaemia-associated cytoplasmic 
NPM mutants (AML NPMc+ proteins) that delocalize ARF to the 
cytoplasm and attenuating the ability of ARF to stabilize p53 and to 
sumoylate both NPM and MDM2 (den Besten et al., 2005 and Colombo et 
al., 2006). 
The ability of NPM to shuttle between the nucleus and cytoplasm, its 
association with maturing pre-ribosomal particles and its effects in 
promoting the processing of ribosomal RNA precursors implicate NPM in 
ribosome biogenesis. ARF retards rRNA transcription and processing, 
interferes with NPM nucleocytoplasmic shuttling and impedes ribosome 
export from the nucleus to the cytoplasm (Brady et al., 2004 and Yu et al., 
2006). (Figure 15) 
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Figure 15. ARF–NPM interactions and ribosomal biogenesis. A | High levels of nucleophosmin 
(NPM) (pink) are expressed in rapidly proliferating cells. Although most NPM is compartmentalized 
within the nucleolus, NPM dynamically shuttles between the nucleus and cytoplasm. NPM is assumed to 
have a key role in ribosomal biogenesis, by facilitating the transport of large (60S) and small (40S) 
ribosomal subunits (green circles) into the cytoplasm, where, together with mRNAs, they form 
polyribosomes required for protein synthesis. B | In cells made quiescent by mitogen deprivation, 
ribosome biogenesis is attenuated and the level of NPM falls. C | In response to oncogenic stress, induced 
ARF protein (blue) binds to MDM2 (yellow), which leads to p53 activation and cell-cycle arrest. ARF 
also enters the nucleolus to form distinct, stable complexes with NPM. One effect of p53 is to inhibit the 
transcription of RNA polymerase I and slowing ribosome biogenesis.The ARF protein antagonizes the 
shuttling of NPM and attenuates ribosome trafficking to the cytoplasm . 
 
1.14 ARF: proteasome and protein turnover 
The discovery that p14ARF can directly interact with regulative 
components of the proteasome multi-protein complex, such as TBP-
1/PMSC3 of the 19S subunit (Pollice et al., 2004; Pollice et al., 2007) and 
REG-γ of the 11S lid (Takaoka et al., 2003) offers a new key to interpret 
the mechanisms through which ARF is regulated and regulates cell growth 
and proliferation. The first evidence of a link between ARF and the 
proteasome is the observation that both human and mouse ARF accumulate 
following treatment with proteasome inhibitors suggesting that ARF 
degradation depends, at least in part, by the proteasome (Kuo et al., 2004). 
A very recent report describes a direct involvement of the REG-γ 
proteasome in a ubiquitin-independent regulation of the ARF turnover 
(Chen et al., 2007) (Figure 16). 
The feature of proteins targeted to the REG-γ pathway is the lack of 
ubiquitination, usually due to the absence of lysine residues. Both p16 and 
human p14ARF are naturally lysine-less proteins. Interestingly, viral 
proteins constitute a substantial subset of naturally lysine-less proteins. 
This raises the hypothesis that the REG-γ pathway might play a role in the 
control of viral pathogenesis. This is particularly interesting, given that 
ARF activation has been linked to viral response (Garcia et al., 2006). 
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Figure 16. A model for the regulation of ARF turnover. ARF can be degraded by the proteasome 
through ubiquitin-independent (by the 20S or 20S/REG-c complex) or dependent (by 26S complex) 
mechanisms. Binding to the 19S subunit PSMC3/TBP-1 protects ARF both in vitro and in cells. 
 
ARF also causes alteration of stability for some binding partners.  
For example, B23/NPM and E2F become degraded by the proteasome in an 
ubiquitin-dependent manner, while the CtBP2 antiapoptotic transcriptional 
co-repressor become degraded by the proteasome in an ubiquitin-
independent manner (Paliwal et al., 2006). Most of other partners become 
sumoylated although a precise function to this modification has not yet 
been assigned (Rizos et al., 2005; Tago et al., 2005; Liu et al., 2007).  
In some cases, ARF is able to stabilize its partners from proteasomal 
degradation. It has been described the ARF’s ability to induce a non-
classical poly-ubiquitination of interacting partners, like Tip60, Topo I and 
COMMD1 (a multifunctional protein involved in copper metabolism and 
apoptosis) that leads to a stabilization of this factors (Huang et al., 2008).  
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Therefore, ARF interaction with the proteasome could serve dual roles: on 
one side it is necessary to regulate ARF protein turnover, while, on the 
other side, it could play a role in bringing ARF interacting partners in 
contact with the ubiquitin/proteasome machinery. 
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CHAPTER II 
 Aim 
 
Myc is a well known proto-oncogene: deregulation of Myc gene expression 
due to amplification or translocation is present in a wide variety of human 
tumours. Since 25 years, from its discovery, Myc has been a pioneer in the 
oncogene field. Myc over-expression induces cell proliferation, cell growth 
and inhibition of cell differentiation. The Myc protein is a transcription 
factor; it exerts all these different effects in the cellular context by 
modulating the gene transcription. It has been extimated that about 1500 
genes in the human genome are Myc-responsive tagets and they are 
compiled in the Myc target gene database. 
The aim of this thesis has been focused to analyze the positive regulation of 
Myc-mediated transcription by P-TEFb elongation complex, and the 
negative control exerted by p14ARF onco-suppressor on Myc’s 
transactivation functions. 
Moreover in a parallel line of research I investigated the p14ARF 
involvement on Tat-mediated transcriptional transactivation of HIV-
1(Human Immunodeficiency Virus 1) gene. 
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CHAPTER III 
Results 
3.1 P-TEFb regulates positively c-Myc transactivation  
 
3.1.1 Myc interacts exclusively with catalytically active P-TEFb 
complex. 
Previous works (Eberhardy and Farnham 2002; Kanazawa et al., 2003) 
have shown that Myc, as transcription factor, in addition to recruit histone 
acetylation activity, binds the positive transcription elongation factor b (P-
TEFb) which consists of the cyclin-dependent kinase CKD9 and its 
regulatory subunit cyclin T1. The highly conserved Myc Box I (MBI) 
interacts directly with Cyclin T1. P-TEFb phosphorylates the carboxyl-
terminal-domain (CTD) of the larger subunit of RNA polymerase II as well 
as negative elongation factors allowing efficient transcription elongation.  
It has been demonstrated that the Myc’s ability to activate transcription of 
cad gene promoter correlates with binding of cyclin T1. 
Moreover it has been shown (Kanazawa et al., 2003) that the inhibition of 
P-TEFb complex blocks the transcriptional activation of Myc target gene as 
well as cellular proliferation and apoptosis induced by Myc.  
The P-TEFb complex is object of studies in the laboratory in which I have 
worked since several years. The P-TEFb complex exists in vivo, in the 
cells, essentially in two forms in dynamic equilibrium between them. A 
light complex with high kinase activity, in which the active P-TEFb is 
composed by CDK9 and Cyclin T1, and the larger complex with low 
kinase activity, in which the two proteins are associates with an inhibitor 
protein called Hexim and with the snRNA 7SK.  
To determine if Myc interacts with the core active or the large inactive P-
TEFb complex, I have performed experiments of co-immunoprecipitation.  
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Transient transfections were performed in human 293T cells using CMV-
Flag-Myc and CMV-CycT1 expression vectors. Cellular extracts were 
prepared and subjected to CoIP experiment with anti-CycT1 or anti-Myc 
antibodies, respectively. As expected Myc, Max, CDK9 and Hexim 
proteins were found in the immunoprecipitated Cyc T1 materials, while 
anti-Myc antibody co-precipitated the associates partner Max as well as 
Cyc T1/CDK9 proteins, but no Hexim protein was detectable in the anti-
Myc cointaining complex (Figure 17 A lane 2-4). These data demonstrated 
that Myc interacts exclusively with ‘core’ active CycT1/CDK9 complex. 
Next, to corroborate these results I have investigated if also the endogenous 
Myc interacts with the P-TEFb complex. I carried out a CoIP analysis with 
cell extracts from 293T cells; as shown in Figure 17 B, the anti-Myc 
antibody co-precipitated Max as well as P-TEFb (CycT1 and CDK9), but 
no HEXIM1 was detectable in the Myc-IP materials. Reciprocally, anti-
CycT1 coprecipitated endogenous Myc/Max, as well as the expected 
partners CDK9 and HEXIM1, whereas the IgG, used as control, did not. 
Moreover, the absence of HEXIM1 protein in the Myc-associated materials 
suggests that Myc interacts, in association with Max, only with the catalytic 
active P-TEFb complex.   
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Figure 17. Myc/Max interacts with P-TEFb. (A) 293T cells were transiently transfected with pcDNA3-
Myc and pcDNA3-CycT1 constructs. Protein extracts were immunoprecipitated with anti-Myc or anti-
CycT1 as indicated, and preimmune antiserum IgG as negative control. Co-IP complexes were analyzed 
by WB with the indicated antibodies. Five percent of the protein input was loaded in lane 1. (B) 293T 
cellular extracts were precipitated with anti-Myc or anti-CycT1, as indicated; and inputs (10%) and 
precipitates (Ips) were analyzed by immunoblotting with the indicated antibodies. 
 
3.1.2 Myc directly recruits P-TEFb to chromatin templates 
The physical interaction between P-TEFb and Myc/Max suggests that Myc 
might recruit P-TEFb at the chromatin of responsive genes upon binding of 
the Myc/Max complex to the E-box (the promoter region). To value this 
hypothesis, I planned to use the well-described Rat1-MycER cell line 
expressing the inducible c-Myc-ER chimera (kindly provided by prof. 
Bruno Amati IEO, Milano). This cell line expresses the inducible c-MycER 
chimera and can be synchronized by starvation in the G0-G1 (quiescence) 
cellular phase, in which it is well documented that c-myc expression is 
virtually undetectable. After mitogenic and/or serum stimulation, c-myc 
mRNA and endogenous c-Myc protein are rapidly induced and cells enter 
the G1 phase of the cell cycle. Moreover, after treatment with 4-
hydroxytamoxifen (OHT) the exogenous c-MycER chimera can be 
activated. Expression of exogenous Myc in cultured fibroblasts promotes 
S-phase entry and shortens G1 phase of the cell cycle, while activation of a 
conditional Myc is sufficient to drive quiescent cells into cell cycle.  
In order to demonstrate if Myc directly recruits P-TEFb to chromatin 
templates of both NUC and CAD genes target, I performed chromatin 
immunoprecipitation (ChIP) assays using Rat1-MycER cells, made 
quiescent by contact inhibition followed by serum removal for two days. 
After two days the cells were treated with 4-hydroxytamoxifen (OHT) to 
determine, during MycER-mediated activation, the in vivo binding of Myc, 
P-TEFb and RNAPII to the E-box of the CAD gene. I assessed their 
presence by using antibodies against Myc and CycT1. As shown in Figure 
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18, upon Myc induction (only 90’ of 4-OHT treatment), I observed a 
concomitant presence of both Myc and P-TEFb at E boxes of CAD 
promoter. 
 
Figure 18. Co-occupancy of Myc and P-TEFb at CAD E-Box. Quiescent Rat-MycER were treated 
with either vehicle or 4-OHT for 90’ and subjected to chromatin immunoprecipitation (ChIP) assays. The 
assays were carried out with the indicated antibodies using amplicon spanning the CAD E-box.17 To 
determine co-occupancy, the CAD E-box region was immunoprecipitated with CycT1 antibody and re-
immunoprecipitated with Myc antibody. The data shown are from a single experiment, and similar results 
were seen in three separate experiments. 
 
Accordingly with previous findings (Frank et al., 2001; Frank et al., 2003), 
I determined that also RNAPII was loaded onto the CAD promoter before 
Myc induction. 
The semi-quantitative nature of these assays was taking in account by 
performing PCR amplification using serial dilutions of DNA template as 
well as by repeating the experiments (2–3 times) using different chromatin 
preparations. In addition, the ACHR promoter was constantly used in all 
experiments as negative control.  
Moreover to determine whether a unique complex containing both Myc and 
P-TEFb is associated to the CAD promoter, I sought to examine possible 
co-occupancy of both factors on CAD E-box. I performed re-ChIP 
experiment in which the CAD E-box region first was immunoprecipitated 
with CycT1 antibody and after re-immunoprecipitated with Myc antibody. 
As shown in Figure 18, co-occupancy of Myc and CycT1 was seen at the 
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CAD promoter in response to 4-OHT treatment. I concluded that Myc 
recruits in vivo P-TEFb at the CAD promoter. 
 
3.1.3 The DRB affects the Myc transactivation functions and blocks 
Myc-induced proliferation and apoptosis  
 
The binding between Myc/Max and active core P-TEFb together with the 
clear evidence of their recruitment on NUC and CAD chromatin templates, 
strongly suggests that Myc/P-TEFb interaction is functional relevant. 
To analyze the involvement of the CDK9 kinase in transcriptional 
regulation driving by Myc, I used 5.6-di-chloro-1-b-D-ribofuranosyl-
bensimidazole (DRB), the pharmacological specific inhibitor of CDK9 
kinase activity .  
To test such premise, I performed the quantitative Real-Time qPCR using 
Rat1 cells expressing a 4-hydroxytamoxifen (OHT)-inducible MycER 
chimera were made quiescent by contact inhibition followed by serum 
removal for two days. After two days the cells were treated with 4-
hydroxytamoxifen (OHT) in the presence or absence of DRB (20 and 50 
μM), and I evaluated the relative levels of expression of two Myc-
responsive target genes, nucleolin (NUC) and CAD as well as two 
housekeeping control genes beta-2M and RPS9 (Figure19). 
All samples were normalized using as control genes (CGs) the 
betaglucuronidase (GUS) and 18 sRNA (Beillard et al., 2003). As 
represented in Figure 19, both NUC and CAD gene expression were up-
regulated by Myc and DRB treatments (at 50 μM) effectively reduced NUC 
and CAD activities. 
Importantly, DRB did not block the expression of the MycER chimera 
following 4-OHT treatment. 
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Figure 19. DRB blocks expression of Myc-target genes. Quiescent Rat-MycER cells were treated with 
4-OHT in the absence or presence of DRB at 20 µM and 50 μM, and total RNA was prepared at the 
indicated times and NUC, CAD RPS9 and beta2M mRNA levels were quantified using qPCR. mRNA 
levels were normalized to GUS mRNA levels. The values are presented relative to RNA levels in 
quiescent Rat-MycER cells. 
 
It has been shown (Kanazawa et al., 2003) that the specific CDK9 inhibitor 
DRB blocks cellular proliferation and apoptosis induced by Myc.  
To determine the functional effects of DRB treatments on the cellular 
changes that occur upon Myc-activation, I performed cell cycle distribution 
by Facs analysis of Rat1 MycER cells. 
It is well known that Myc induces S-phase and apoptosis of quiescent cells 
grown in low serum. As shown in Figure 20, after 18 hrs of 4-OHT 
treatment it is evident the activation of Myc, and Myc induces proliferation 
(percent of S-phase) and apoptosis (percent of sub-G1 cells), in black, 
while DRB treatments inhibits both Myc-induced proliferation and 
apoptosis. In particularly, treatment with DRB at 50µM affects cell 
viability. These results strongly suggest that CDK9 is crucial for the 
induction of Myc-responsive gene as well as for Myc-induced cellular 
outcomes. 
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Figure 20. DRB affects Myc-induced proliferation and apoptosis in Rat cells. (A) Quiescent Rat-
MycER cells were treated with 4-OHT in the absence or presence of DRB at 20 µM and 50 μM as 
indicated. After 18 hrs of treatment cells were collected and cell cycle distribution was analyzed by 
FACS. (B) Actively growing Rat-MycER cells were treated with DRB and cells were collected after 18 
hrs and analyzed by FACS. 
 
3.1.4 The distribution of RNA Pol II, Myc and P-TEFb in vivo are 
differentially impaired by DRB treatment 
DRB treatment provided circumstantial evidence that Myc/P-TEFb 
interaction is functional relevant. Both Myc-induced cellular physiological 
changes and expression of Myc-target genes were effectively and 
specifically inhibited by DRB. It is pertinent to note that previous studies 
showed that DRB effectively blocks CDK9 activity, and, to lesser extent, 
other CDKs (Dai et al., 2003). Then, the contribution of other kinases to the 
inhibition of Myc-responsive genes cannot be strictly excluded. 
To assess the role of CDK9 activity, I investigated the distribution and the 
relative presence of Myc, P-TEFb and Pol II at the E-box promoter 
sequences as well as in the coding regions of CAD and NUC genes after 
DRB treatment.  
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To this end, I performed chromatin immunoprecipitation (ChIP) 
experiments that were analyzed by semiquantitative PCR, and quantitative 
Real-Time PCR, and both methods gave similar results. For RNA Pol II 
immunoprecipitation, I used three different anti Pol II antibodies (8WG16, 
H14 and H5) which recognize different epitopes of the CTD. 8WG16 was 
used to follow total Pol II, while the phosphorylated Pol II was detected by 
H14, recognizing phosphor-Ser-5 CTD. The distribution of the Ser-2 
residues of the CTD was assessed using the H5 antibody.  
As represented in Figure 21 A and B, either 4-OHT and DRB treatment led 
to the same results at the E-box region of both CAD and NUC genes, in the 
similar distribution of Myc, Pol II and P-TEFb. This results suggest that 
recruitment of these factors to chromatin do not require CDK9 catalytic 
activity. In contrast, clearly DRB treatment reduces the density of Ser-2 
CTD, but does not affect the density of Ser5 CTD. This result corroborates 
the results obtained by expression analysis of these genes after DRB 
treatment. This demonstrate that P-TEFb-mediated phosphorylation of 
Ser-2 CTD is a key control step for transcription of Myc-target genes. 
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Figure 21. DRB affects CTD phosphorylation. A. Quiescent Rat-MycER were treated with either 
vehicle or 4-OHT in the presence or absence of DRB (50 µM) for 90’ and subjected to chromatin 
immunoprecipitation (ChIP) assays using the indicated antibodies. Immunoprecipitated material was 
analyzed by Real Time PCR using sets of primers against regions of NUC encompassing E-Box (+574) 
and coding region (+1500) and CAD gene E-Box and coding region (+3258).B. Schematic representation. 
 
3.2 Myc/p14ARF interaction impairs Myc functions 
3.2.1 Biochemical characterization of the c-Myc/p14ARF interaction 
The first oncogene identified to regulate ARF tumour suppressor function 
is Myc (Zindy et al., 1998). Overexpression of Myc in B-lymphocytes 
augments cell proliferation which is counteract by the ARF-p53-Mdm2 
axis. Inhibition of this axis suppresses Myc-induced apoptosis and 
facilitates B cell lymphoma formation (Eischen et al., 1999). This findings 
indicate that Myc-induced cell growth and proliferation is balanced by 
simultaneous activation of p53 via ARF. However, several observations 
suggest that this pathway is not so simple. ARF induction requires very 
high and sustained Myc activity and physiological level of Myc does not 
activate the ARF promoter (Cleveland and Sherr 2004). Cells with p53-null 
or p53-mutated status have marked upregulation of murine p19ARF, which 
is suppressed by overexpression of p53 and p53 also inhibits Myc 
expression (Sherr et al., 2000). Thus, there is a feedback regulation among 
these proteins the balance of which determines the ultimate fate of the cells. 
Adding to this complexity, it has been demonstrated (Qi et al., 2004; Datta 
et al., 2004) that mouse p19ARF interacts with c-Myc independently of 
MDM2 or p53 and negatively regulates its transcriptional activity. 
Interaction of Myc with p19ARF relocates p19ARF from the nucleolus to 
nucleoplasm in both wild-type and p53-null MEFs. The structural 
differences between the murine p19ARF and the human p14ARF proteins 
prompted me to determine if also the human p14ARF tumour suppressor 
protein was associated with the human c-Myc protein. To this end, I 
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performed in vitro interaction assays using highly purified bacterial 
expressed HA-Myc-FLAG and GST-p14ARF proteins. Equal amounts of 
the two purified proteins were incubated for 3 hours and subsequently the 
HA-Myc-FLAG protein complex was recovered with M2-FLAG beads and 
analyzed by western blotting with the GST antibody for the presence of the 
GST-p14ARF co-purified protein. The HA-Myc-FLAG was incubated with 
GST and GST-Max proteins as negative and positive interaction controls, 
respectively (Figure 22 A, lane 1 and 2). In addition, equal amounts of the 
GST, GST-Max and GST-ARF were incubated, in absence of the bait Ha-
Myc-FLAG, with M2-FLAG beads as control of aspecific purification 
(lane 4, 5 and 6). The result demonstrated that Myc directly interacts with 
p14ARF (lane 3). 
Interaction between Myc and p19ARF has also been shown to alter the 
transcription activity of Myc, as described in the background chapter. Since 
Myc binds to target promoters as heterodimer with Max, I sought to 
determine if p14ARF was able to bind to the Myc-Max heterodimer and if 
this interaction was putative mutually exclusive. Purified GST-p14ARF, 
HA-Myc-FLAG and His-Max proteins were mixed together and then the 
proteins subjected to GST-pull down. The GST-affinity-purified complex 
(AC) was then analyzed for the presence of Myc and Max proteins by 
immunoblotting with anti-Myc and anti-His antibodies, respectively. The 
result in Figure 22 B lane 2, shows that the GST-p14ARF associated with 
both Myc and Max, demonstrating that p14ARF interacts with the Myc-
Max complex and that the binding of p14ARF does not interfere with Myc-
Max interaction in vitro. 
 Gargano B. 
 
Figure 22: p14ARF directly interacts with Myc in vitro. (A) The GST, GST-Max or GST-p14ARF 
proteins (600ng) were incubated in presence (lane 1, 2, 3) or absence (lane 4, 5, 6) of HA-Myc-FLAG 
bait protein (600ng). Protein complexes were recovered by immunoaffinity with ANTI-FLAG M2-
Agarose and analyzed by WB with anti-FLAG (top panel) and anti-GST (bottom panel) (Santa Cruz 
Biotechnology, Inc.). In lanes 8, 9, 10, 5% of the inputs were loaded. (B) GST-p14ARF and GST-Max 
proteins (600ng) were incubated with equal amounts of GST (lane 1) or HA-Myc-FLAG (lane 2). 
Affinity complexes (AC) were analyzed by WB using anti-GST (top panel) and a mixture of anti-Myc 
plus 6xHis Monoclonal Antibody (BD Biosciences, bottom panel). 
 
3.2.2 Myc Box II is required for Myc-ARF interaction in vivo and in 
vitro 
To identify c-Myc protein sequences that are essential for association with 
p14ARF, I performed in vitro GST pull down assays using the His-
p14ARF protein and various GST-Myc deletion mutants. The different 
GST-Myc deletion mutants purified, described in Figure 22, were mixed 
with the His-p14ARF protein and the complexes were affinity-purified by 
GST beads; the presence of p14ARF was monitored by immunoblotting 
with His antibody. Aliquots of each sample were assayed with the GST 
antibody for the presence of the different GST-Myc mutants used as baits. 
The results represented in Figure 23 show that the Myc deletion mutants 1-
143 and 1-228 (lane 4-5) retain the ability to bind the His-p14ARF protein. 
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In particular, the GST-Myc 1-228 shows stronger interaction (lane 5). In 
contrast, the N-terminal deletion mutants, GST-Myc 151-340 and GST-
Myc 262-439 fail to bind His-p14ARF (lane 6, 7). As positive control of 
interaction the GST-Myc 262-439 interacts with His-Max (lane 8). Thus, 
the Myc residues 103 to 151, including the Myc BoxII domain, are required 
for association with p14ARF in vitro. 
 
Figure 23 : Mapping of the Myc domains involved in ARF interaction. (A) His-p14ARF was 
incubated with GST and GST-Myc deletion mutants (lane 1, 2, 3, 4, 5, 6, 7) proteins. In lane 8, as positive 
control of Myc interaction, GST-Myc 262-439 was incubated with the His-Max. The protein complexes 
were recovered using glutathione-sepharose and the copurified proteins revealed with anti-His (top panel) 
and anti-GST (bottom panel). In lane 9 and 10, 5%of the proteins inputs were loaded. (B) Schematic 
representation of the Myc full-length protein and deletion mutants. The relative strengths of interactions 
with p14ARF are indicated. 
 
 47
 Gargano B. 
To determine whether Myc/Max heterodimer interacts with p14ARF in 
vivo, Co-IP assays were performed with protein extracts from transiently 
transfected 293T cells that express low levels of endogenous Myc and ARF 
proteins. The cells were transfected with CMV-based Myc and Max 
expression vectors in the presence and absence of p14ARF, and 
immunoprecipitations performed using anti-Myc or anti-Max antibodies. 
Immunoblot analysis was then performed using ARF antibody. The results 
reported in Figure 24 A, show that either the p14ARF (lane 10) and Max 
(lane 9, 10) proteins co-immunoprecipitated with Myc. In parallel the 
extracts were immunoprecipitated with the Max antibody followed by 
immunoblotting with Myc, Max and ARF antibodies, respectively. As 
shown in Figure 24 B, Max immunoprecipitated extracts contained both 
the Myc and the ARF proteins (lane 12). Collectively these findings 
demonstrate that p14ARF associates with Myc/Max heterodimer in vitro 
and in vivo and that Myc binding to Max and p14ARF is not mutually 
exclusive. To further validate the Myc-ARF interaction the U2OS cell line, 
which does not express the ARF protein, was transfected with CMV-based 
Myc and ARF expression vectors and cellular extracts were 
immunoprecipitated with the ARF antibody. Immunoblotts confirmed the 
presence of the Myc protein in the immunoprecipitated extracts (Figure 24 
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C lane 6). 
 
 
Figure 24: p14ARF interacts with Myc in vivo. (A) 293T cells were co-transfected by the calcium–
phosphate method with pcDNA3-FLAG-Myc, pcDNA3-Max and pcDNA-ARF-HA as indicated. Protein 
extracts were immunoprecipitated with the anti-Myc N262 antibody (lane 6-10), and IgG antibody (lane 
11). The copurified complexes analyzed by WB with anti-Myc 9E10, anti-Max and anti-ARF antibodies, 
as indicated. 5% of the proteins inputs were loaded in lanes 1-5 (B) 293T cells were co-transfected by the 
calcium–phosphate method with of pcDNA3-FLAG-Myc, pcDNA3-Max and pcDNA-ARF-HA as 
indicated. Protein extracts were immunoprecipitated with the anti-Max antibody (lane 7-12), and IgG 
antibody (lane 13). The copurified complexes analyzed by WB with anti-Myc 9E10, anti-Max and anti-
ARF antibodies, as indicated. 5% of the proteins inputs were loaded in lanes 1-6. (C) U2OS cells were 
co-tranfected with the indicated vectors and protein extracts were IP with anti-ARF antibody (lane 4, 5, 6) 
and the Co-IP complexes analyzed by WB with anti-Myc (top) and anti-ARF (bottom). 5% of the proteins 
inputs were loaded in lanes 1- 3.  
 
To corroborate the requirement of the Myc Box II in the interaction with 
p14ARF, I performed Co-IP assays with protein extracts prepared from 
293T cells that were transiently co-transfected with a CMV driven p14ARF 
expression vector along with the pcDNA3-FLAG-Myc vector expressing 
the full-length protein or an isogenic vector, pcDNA3- FLAG-MycΔ123-
151, expressing a protein with an in-frame deletion of the Myc BoxII 
domain. Protein extracts were immunoprecipitated with the FLAG antibody 
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followed by immunoblot with the ARF and Max antibody, respectively. 
The results shown in Figure 25, illustrate that while the full-length Myc 
protein interacts with both p14ARF and Max (lane 3), the deletion of aa 
123 to 151, including the Myc BoxII, severely invalidates the Myc-ARF 
binding, without significant effects on Max binding (lane 4). Collectively, 
these results substantiated the physical interaction between ARF and Myc 
and demonstrate that the region encompassing the Myc BoxII is involved in 
the interaction between Myc and p14ARF both in vitro and in vivo. 
 
 
Figure 25. Myc Box II is required for the Myc-ARF interaction in vivo. (A) 293T cells were co-
transfected with pcDNA-p14ARF-HA along with pcDNA3-FLAG-Myc or pcDNA3-FLAG-MycΔ123-
151 as indicated. Protein extracts from the transfected cells were IP with ANTI-FLAG M2-Agarose 
followed by WBs with anti-Myc (top), anti-Max (middle) and anti-ARF (bottom). (B) Schematic 
representation of Myc deletion mutant is shown. 
 
3.2.3 Myc-p14ARF nucleolar co-localization is abrogated by MBII 
deletion 
The Myc protein localizes in the cellular nucleus while the p14ARF protein 
has a predominantly nucleolar localization. Overexpression of Myc-
induced relocalization of p19ARF out of the nucleolus and into the 
nucleoplasm in MEF cells, or conversely p19ARF could delocalize Myc 
into the nucleolus in U2OS cells. Even though the functional meaning is 
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still obscure, this behaviour can be instrumental to determinate if the Myc 
BoxII domain has in vivo sub-cellular relevance in the Myc-ARF 
interaction. Consequently, I sought to analyze the contribution of the Myc 
BoxII region, required for in vivo and in vitro binding, in the sub-cellular 
co-localization of Myc and p14ARF. U2OS cells, that do not express the 
p14ARF, were co-transfected with a green fluorescent protein (GFP) 
fusion, GFP-p14ARF, along with the Myc expression vector or the deletion 
mutant MycΔ123-151. In agreement with previous observations, I found 
that the GFP-p14ARF accumulates predominantly into the nucleolus 
whereas Myc displayed typical nucleoplasmatic localization. When ARF 
and Myc were co-transfected in a 1 to 1 ratio, 82% of the co-transfected 
cells exhibited co-localization of Myc and ARF protein into the nucleoli 
(Figure 26 A). In contrast, a significant reduction of co-localization into 
the nucleoli (22%) was observed when GFP-p14ARF was co-transfected 
with the MycΔ123-151 deletion mutant (Figure 26 B). These findings 
underlie the relevance of the Myc BoxII domain in the physiological 
interaction between the ARF and Myc protein. 
 
 
Figure 26. Myc-ARF nucleolar colocalization is impaired by Myc BoxII deletion. U2OS cells were 
co-transfected with GFP-p14ARF and pcDNA3-FLAG-Myc (A) or pcDNA3-FLAG-MycΔ123-151 (B) 
by Lipofectamine 2000 as indicated. An example of immunofluorescence microscopy of the cells 
immunostained with anti-Myc 9E10 and analyzed by fluorescence microscopy as previously described, is 
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shown. At least 150 cells were analyzed in each experiment. Values are means from three independent 
experiments. 
 
3.2.4 p14ARF N-terminal domain interacts with c-Myc 
In the attempt to define the ARF region involved in Myc interaction, I 
subcloned the ARF cDNA regions coding for aa 1 to 65 and for aa 65 to 
132 in a FLAG epitope tagged CMV10 vector. These constructs and the 
wild type p14ARF vector were transfected alone or in combination with c-
Myc expression vector into 293T cells. The protein extracts from the 
transfected cells were immunprecipitated with the c-Myc antibodies and the 
coimmunoprecipitated proteins analyzed by WB with c-Myc, Max and 
FLAG antibodies. The results shown in Figure 27 demonstrate that either 
the WT ARF protein then the protein encoding for the first 65 aa co-
immunoprecipitate with c-Myc (lane 1, 2 respectively). In contrast the 65-
132 ARF C-terminal domain is impaired in binding to Myc protein (lane 3). 
As control of c-Myc immunoprecipitation, WB with Max antibody 
confirms the presence of the endogenous Max protein in all the Myc 
immunopreciptated extracts. 
 
 
Figure 27.  Myc interacts with the N-terminal region of p14ARF. 293T cells were co-transfected with 
pcDNA3-FLAG-Myc, p3xFLAG-ARF full length or p3xFLAG-ARF1-65 or p3xFLAG-ARF65-132 as 
indicated.  Protein extracts were immunoprecipitated with the anti-Myc N262 antibody (lane 1-3), and 
IgG antibody  (lane 4 and 5) and the copurified complexes analyzed by WB with anti-Myc 9E10, anti-
Max and anti-FLAG antibodies, as indicated. 5% of the proteins inputs were loaded in lanes 6-8. 
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3.2.5 Biochemical characterization of the N-Myc/p14ARF interaction 
The data reported in the previously paragraphs demonstrated that p14ARF 
directly associates with the c-Myc protein. Even if is general assumption 
that the interaction partners of c-Myc are also N-Myc partners, the failure 
of expression of either two Myc family members is not redundant and it 
cannot be excluded that they can form different complexes with their 
interactors. 
In order to investigate if p14ARF is also a N-Myc partner, CoIP assays 
were performed with protein extracts from 293T transiently transfected 
cells. The cells were transfected with different combinations of CMV-
based expression vectors for p14ARF and N-Myc as reported in Figure 28 
and immunoprecipitations were performed using the N-Myc antibodies. 
The results show that p14ARF co-immunoprecipitates with N-Myc (Figure 
28 A lane 4). In parallel the extracts were immunoprecipitated with the 
ARF antibody followed by immunoblotting with Myc, and ARF antibodies, 
respectively. The results show that ARF immunoprecipitated extracts 
containing the Myc protein (Figure 28 B lane 4). 
 
 
Figure 28. p14ARF interacts with N-Myc in vivo. A. 293T cells were transfected with 3xFLAG-ARF or 
co-transfected with N-Myc and p3XFLAG-ARF F.L. as indicated. Protein extracts were 
immunoprecipitated with the N-Myc antibody (lane 3, 4) and anti IgG (lane 5) as control and the co-
purified complexes analyzed by WB with anti-N-Myc   anti-FLAG   antibodies, as  indicated. 5% of the 
proteins inputs were loaded in lanes 1 and 2. B. The same protein extracts utilized in panel A were IP 
with the anti-ARF antibody (lane 3, 4) and anti IgG (lane 5) as control and the Co-IP complexes analyzed 
by WB with anti-N-Myc and anti-FLAG antibodies. 5% of the proteins inputs were loaded in lanes 1, 2.  
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3.2.6 Myc Box III is required for in vivo N-Myc-ARF interaction 
To identify N-Myc sequences involved in N-Myc-ARF interaction, I 
performed CoIP analysis using protein extracts from 293T cells transiently 
co-transfected with a FLAG tagged p14ARF expression vector and several 
N-Myc deletion mutants expressing different domains of the N-Myc 
protein as indicated in Figure 29B. The protein extracts were 
immunoprecipitated with the ARF antibody and the co-immunoprecipitated 
proteins analyzed by WB with N-Myc and ARF antibodies. As shown in 
Figure 29A, the N-Myc deletion mutant d(1-300) lost the ability to 
associate with p14ARF (lane 10) while all the other mutants and in 
particular the N-Myc d (1-134), whose deletion covers part of the deletion 
of the N-Myc d(1-300), are able to bind p14ARF. From these data I can 
conclude that the N-Myc region involved in p14ARF interaction resides in 
the region from aa 140 to aa 300 containing the MBIII conserved domain. 
 
 
Figure 29. p14ARF interacts with the MBIII of N-Myc in vivo. A 293T cells were co-transfected with 
3xFLAG-ARF and different N-Myc delection mutants as indicated. Protein extracts were 
immunoprecipitated with the ARF antibody (lane 8-14) and anti IgG (lane 15) as control and the co-
purified complexes analyzed by WB with anti-N-Myc anti-FLAG antibodies, as indicated. 5% of the 
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proteins inputs were loaded in lanes 1-7. B Schematic representation of the N-Myc full-length protein and 
deletion mutants. The relative strengths of interactions with p14ARF are indicated. 
 
3.2.7 N-Myc co-localizes with p14ARF in nucleoli upon ARF 
overexpression 
As shown, c-Myc and ARF co-localize in the same cellular compartment 
upon ARF overexpression. Depending from the cell lines analyzed by 
different authors, Myc binding relocalizes ARF from the nucleolus to the 
nucleoplasm or c-Myc co-localizes with p14ARF into nucleoli. In order to 
investigate if also N-Myc could co-localize with ARF in the same cellular 
compartment, I transfected the neuroblastoma cell line SKNBE with the 
GFP-p14ARF expression vector and I analyze the localization of the GFP-
ARF and N-Myc proteins. As expected the GFP-ARF protein in these cells 
shows a predominantly nucleolar localization while the endogenous N-Myc 
protein was barely detectabled by immunocytochemistry analysis. I 
therefore decided to restrict the analysis to co-transfected cells. SKNBE 
cells were transfected with the N-Myc expression vector alone or in 
combination with the GFP-p14ARF. In cells transfected with N-Myc the 
protein was found exclusively in the nucleolar compartment and cells 
transfected with the GFP-ARF alone showed a predominantly nucleolar 
localization of the exogenous ARF protein. 
In cells co-transfected with the two expression vectors, the GFP-p14ARF 
protein retains the nucleolar localization while the N-Myc protein was 
found in the nucleolar compartment in 78% of the co-transfected cells as 
shown in Figure 30A. I then tested the ability of the N-Myc d (1-300) 
protein that I have found impaired in binding to the ARF protein, to be 
recruited by ARF in the nucleoli upon ARF overexpression. 
As shown in Figure 30B, in the cells co-transfected with both GFP-
p14ARF and N-Myc d (1-300) mutant, the GFP-ARF protein was found in 
 55
 Gargano B. 
the nucleoli and the mutated N-Myc protein was found in the nuclear 
compartment.  
These data corroborated the findings that the N-terminal region of the N-
Myc protein was involved in binding with ARF and that the N-Myc 
protein, impaired in ARF binding, lost the capability to be recruited by 
ARF in the nucleoli. 
 
 
Figure 30. N-Myc-ARF nucleolar colocalization is impaired by Myc BoxIII deletion. SKNBE cells 
were co-transfected with GFP-p14ARF and N-Myc  (A) or N-Myc  d(1-300)  mutant  (B) as indicated. An 
example of immunofluorescence microscopy of the cells immunostained with anti-N-Myc and analyzed 
by fluorescence microscopy as previously described, is shown. At least 150 cells were analyzed in each 
experiment. Values are means from three independent experiments. 
 
3.2.8 p14ARF inhibits c-Myc and N-Myc transcriptional activation 
As mentioned in the background chapter, mouse p19ARF is able to block 
Myc’s ability to activate transcription. Furthermore, I decided to investigate 
if p14ARF, the human homolog, was able to inhibit both c-Myc and N-
Myc transcriptional activity. First of all, I investigated if p14ARF 
expression was able to inhibit Myc ability to transactivate the Telomerase 
Reverse Transcriptase (hTERT) promoter. To this end, I cotransfected the 
U2OS cell line with hTERT-luc construct, in which the luciferase gene is 
under hTERT promoter control and with c-Myc in presence of increasing 
amount of the p14ARF vector. As reported in Figure 31A, Myc exogenous 
expression in U2OS cells activates three fold the hTERT-Luc promoter 
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expression (lane 2) and co-transfection of p14ARF inhibits Myc-activation 
in a dose dependent manner (lane 3, 4 and 5). As control, p14ARF alone 
was co-transfected with hTERT-luc. As shown in Figure 31 A (lane 6), 
p14ARF does not have any influence of hTERT promoter transcription in 
the absence of exogenous c-Myc. 
In order to extend these findings to N-Myc-mediated transcriptional 
activation, I took advantage of the Tet21N cell line (kindly provided by 
Prof G. Della Valle) that stably expresses the N-Myc protein in the absence 
of tetracycline. N-Myc expression can be down regulated, to the complete 
absence of expression, by addition of tetracycline in the medium for at least 
48 hours. In this way N-Myc expression can be modulated by the different 
amount of tetracycline. Tet21N cells were grown in the presence of 
tetracycline for 2 weeks to abrogate N-Myc expression and co-transfected 
with the hTERT-Luc construct and an expression vector for p14ARF. Then 
tetracycline was removed from the medium for N-Myc expression. Cells 
were then left untreated or treated with tetracycline and extracts analyzed in 
luciferase assay for the human Telomerase promoter (hTert) driven 
luciferase expression. As reported in Figure 31B, N-Myc activates the 
hTERT promoter three fold (lane 2) and p14ARF was able to inhibit with a 
dose responsive effect the N-Myc mediated activation of the Telomerase 
promoter (lane 3, 4 and 5). Finally, altogether those findings demonstrated 
that p14ARF was able to repress both c-Myc and N-Myc transcriptional 
activities. 
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Figure 31. ARF expression inhibits c-Myc and N-Myc activated transcription. A U2OS cells were 
cotransfected with 100ng of hTERT-Luc, 200ng pMT2T-Myc and different amounts (0,1; 0,5 and 1μg, 
respectively) of pcDNA-p14ARF-HA as indicated. Each histogram bar represents the mean of three 
independent transfections made in duplicate with a standard deviation less than 10%. B Tet21N cells were 
grown in the absence  (High N-Myc, “+”) or presence  (Low N-Myc, “-”) of tetracycline for 2 weeks and 
co-transfected with the hTERT-Luc construct (100 ng) and different amounts (0,1; 0,5 and 1μg, 
respectively) of pcDNA-p14ARF-Haas indicated. Each histogram bar represents the mean of three 
independent transfections made in duplicate with a standard deviation less than 10%. 
 
 
3.3 p14ARF antagonizes HIV-1 Tat protein functions 
 
3.3.1 p14ARF affects Tat transactivation on the HIV-1 promoter 
In a parallel line of research I have deepened a recently discovered and 
unexpected role of tumor suppressor ARF in viral infection surveillance. 
ARF expression is induced by interferon and after viral infection. ARF  
protects against viral infection through a mechanism that involves ARF-
induced release of PKR from nucleophosmin complexes (Garcia et al., 
2006). 
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ARF is a potent tumour suppressor that blocks cell-cycle progression by 
directly binding to, and interfering with, the p53 negative-regulator Mdm2 
(Hdm2 in human), thereby stabilizing and activating p53 (Kamijo et al., 
1997; Stott et al., 1998). The proto-oncoprotein Hdm2 also interacts with 
HIV-1 Tat protein and mediates its ubiquitination in vivo and in vitro (Bres 
et al., 2003). The E3 ubiquitin ligase Hdm2 is a positive regulator of Tat-
mediated transactivation, indicating that the transcriptional properties of 
Tat are stimulated by ubiquitination (post-translate modification). Because 
ARF interacts with Hdm2 and interferes with its activity leading to p53 
stabilization, I sought to determine whether ARF could affect Tat 
transactivation of the HIV-1 promoter. 
HIV-1 Tat-mediated transcription as well as P-TEFb complex are object of 
study in the Prof. Lania-Majello laboratories since several years. 
Transcription of HIV-1 proviral DNA by RNAPII is controlled primarily at 
the level of elongation by the viral Tat protein (Barboric and Peterlin 
2005). Cyclin T1 was originally identified as a direct binding partner of the 
HIV-1 Tat protein in HeLa nuclear extracts, and Tat and Cyc T1 cooperate 
to recruit P-TEFb to the viral 5’ TAR RNA (Price 2000; Saunders et al., 
2006).  
Tat is a protein encoded by the HIV-1, transcribed from multiply spliced 
viral RNA molecules expressed at early stages of viral gene expression. It 
is composed of the two exons of the viral Tat gene and encodes a protein of 
approximately 101 amino acids and in the late stage of the infection cycle, 
a carboxy-terminally truncated, encoded for Tat protein of 72 aminoacids 
also sufficient to transactivate the HIV-1 promoter.  
The aim of this line of research it has been to demonstrate if the ARF 
tumour suppressor could affect Tat protein functions as the Tat 
transactivation of the HIV-1 LTR promoter.  
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To address this point, I carried out transient co-transfection experiments in 
H1299 cells, in HeLa HL6 cells (containing the Luc gene under the control 
of and integrated HIV-1 LTR), and in H358/Tet-On-ARF cells, in which 
doxycycline (Dox) treatment induces a strong expression of p14ARF 
protein (this cell line was kindely provided by Dr. S. Gazzeri). As shown in 
Figure 32, in all cell lines tested p14ARF over-expression inhibits Tat 
transactivation of the HIV-1 promoter.  
Moreover to map the minimal region essential for Tat repression, I 
performed co-transfection experiments using the F:ARF(1-65), F:ARF(65-
132) constructs which contain the p14ARF cDNA regions coding for aa 1 
to 65 and for aa 65 to 132 in a FLAG epitope tagged CMV10 vector, 
respectively. I found that overexpression of F:ARF(1-65) protein 
negatively affected Tat transactivation, while the F:ARF(65-132) protein 
did not. These findings suggest that the N-terminal region of ARF is 
required for ARF-mediated Tat repression.  
 
 
Figure 32. p14ARF expression inhibits Tat transactivation of the HIV-1 promoter. (A) H1299 cells 
were cotransfected with G5-83HIV-Luc (100 ng), Tat101-wt (10 ng) and F:p14ARF(1 μg), F:p14ARF 
(1–65) (1 μg) and F:p14ARF (65–132) (1 μg), as indicated. (B) HL6 cells were cotransfected with Tat-
101 wt (1 μg) F:p14ARF(1 μg). (C) H358/Tet-On/p14ARF inducible cells were treated for 72 hr with or 
without 1 μg/ml doxycycline and then cotransfected with G5-83HIV-Luc (100 ng) and F:Tat-101 wt (10 
ng). Each histogram bar represents the mean of three independent transfections made in duplicate. 
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3.3.2 p14ARF promotes Tat degradation 
The discovery that p14ARF can directly interact with regulative 
components of the proteasome multi-protein complex, such as TBP-
1/PMSC3 of the 19S subunit (Pollice et al., 2007) and REG-γ of the 11S lid 
(Takaoka et al., 2003) offers a new key to interpret the mechanisms 
through which ARF is regulated and regulates cell growth and 
proliferation. The first evidence of a link between ARF and the proteasome 
is the observation that both human and mouse ARF are accumulated 
following treatment with proteasome inhibitors, suggesting that ARF 
degradation depends, at least in part, by the proteasome (Kuo et al., 2004). 
A very recent report describes a direct involvement of the REG-γ 
proteasome in an ubiquitin-independent regulation of the ARF turnover 
(Chen et al., 2007). REG-γ pathway plays a role in the control of viral 
pathogenesis and this is particularly interesting, given that ARF activation 
has been linked to viral response (Garcia et al., 2006). 
It has been reported that Hdm2 interacts with Tat and mediates 
polyubiquitination of Tat in vitro and in vivo (Bres et al., 2003; Lassot et 
al., 2007) One highly conserved lysine, lysine 71, functions as the major, 
ubiquitination site in Tat. Moreover, Hdm2 overexpression enhances Tat 
activity, thus it functions as a positive Tat co-activator. Since Hdm2 is 
negatively regulated by p14ARF, a possible mechanism of p14ARF 
repression might involve an interference of Hdm2-mediated ubiquitination 
of Tat. Accordingly with previous data (Bres et al., 2003), I found that 
Hdm2 enhances Tat transactivation, while p14ARF represses Tat (Figure 
33A). Overexpression of Hdm2 fails to relieve p14ARF repression of Tat 
activity, indicating that Hdm2 over-expression does not counteract the 
negative function of p14ARF.  
The main function of Hdm2 in Tat-mediated transactivation is to attach 
covalently ubiquitin chain to Tat. The fusion construct in which a ubiquitin 
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chain is attached to Tat protein bypasses the requirement of Hdm2 in Tat 
transcriptional activation. Then I wished to demonstrate if p14ARF could 
interfere with Hdm2-mediated ubiquitination and the transactivation 
capabilities of Tat-Ub fusion protein should be refractory to p14ARF 
inhibition. To verify this hypothesis, I tested the relative transactivation 
abilities of Tat, Tat-Ub and TatK71R-Ub proteins in the presence or 
absence of p14ARF. The Tat-Ub vector presents a poliubiquitin chain fused 
to C-terminal domain of Tat protein, while TatK71R-Ub vector presents 
one mutation in lisine 71, replaced with arginine, that affects this main 
poliubiquitination site. I found that Tat wild-type as well as the Tat-Ub 
fusions were repressed by p14ARF (Figure 33B), suggesting that p14ARF-
mediated repression of Tat transactivation is not dependent on 
ubiquitination process.  
 
Figure 33. p14ARF expression inhibits Hdm2 enhanced Tat-mediated transactivation of the HIV-1 
promoter. (A) 293T cells were cotransfected with G5-83HIV-Luc (100 ng), F:Tat-101 wt (10 ng), 
F:p14ARF (500 ng) and CMV-Hdm2 (500 ng), as indicated. (B) p14ARF expression down regulates 
F:Tat101-wt, pTatWt-Ub and pTatk71R-Ub fusion proteins. 293T cells were cotransfected with -83HIV-
Luc (100 ng), F:Tat-101 wt, pTatWt-Ub fusion protein or pTatk71R-Ub fusion protein (10 ng in each 
case) and in the presence or absence of F:p14ARF (500 ng) as indicated. Each histogram bar represents 
the mean of three independent transfections made in duplicate. 
 
ARF also causes alteration of stability for some binding partners.  
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For example, B23/NPM, E2F1, E2F3 and Mdm2 become degraded by 
induction of the proteasome (26S) in an ubiquitin-dependent manner, while 
the CtBP2 antiapoptotic transcriptional co-repressor becomes degraded by 
the proteasome in a ubiquitin-independent manner (Paliwal et al., 2006). 
Most of other partners become sumoylated although a precise function to 
this modification has not yet been assigned (Rizos et al., 2005; Tago et al., 
2005; Liu et al., 2007).  
On the contrary in some cases, ARF is able to stabilize its partners (Tip60, 
Topo I and COMMD1) through proteasomal degradation inducing a non-
classical poly-ubiquitination (Huang et al., 2008).  
Therefore, it is possible that p14ARF-mediated inhibition of Tat 
transactivation is due to reduced levels of Tat protein. In order to evaluate 
the influence of p14ARF on the accumulation of Tat protein, the relative 
amounts of the Tat protein were determined in the presence of increasing 
amounts of p14ARF. I co-transfected 293T cells with a F:Tat vector 
together with increasing amount of p14ARF expression vector and cell 
extracts were analyzed by immunoblotting. As reported in Figure 34A, Tat 
protein levels decrease in the presence of p14ARF and the reduction is 
inversely correlated to the amounts of co-transfected and expressed 
p14ARF protein. Quantitative RT-PCRs of Tat mRNA isolated from the 
transfected cells clearly showed that p14ARF does not affect Tat 
transcription (Figure 34B), suggesting that p14ARF inhibitory effect is 
exerted at posttranscription level. To determine whether p14ARF induced 
reduction of Tat levels was due to proteasome-mediated degradation and to 
avoid the inherent limitation of co-trasfection experiments, I used the 
H358/Tet-On-ARF cells in which endogenous p14ARF protein could be 
induced by Dox treatment. 
p14ARF expression was induced in the presence of Dox for two days, then 
Tat vector was transfected into Dox-treated and untreated H358/Tet-On-
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ARF cells and protein levels were determined in the absence o presence of 
the proteasome inhibitor MG132. As shown in Figure 34C, MG132, 
interfered significantly with the ability of p14ARF to destabilize Tat in the 
H358/Tet-On-ARF cells.   
Next, I determined the stability of the Tat-Ub and TatK71R-Ub fusion 
proteins in the presence of p14ARF. 
Dox-treated and untreated H358/Tet-On-ARF cells were transfected with 
Tat-Ub and TatK71R-Ub vectors and the relative amounts of Tat proteins 
monitored by immunoblotting. As shown in Figure 34D p14ARF-mediated 
reduction of Tat protein levels was observed with both Tat-Ub and 
TatK71R-Ub fusion proteins. Collectively, these results suggest that 
p14ARF-mediated reduction of Tat protein is unaffected by the 
ubiquitination status of the Tat protein. 
 
Figure 34. p14ARF targets Tat for degradation. (A) 293T cells were co-transfected whit Tat-101 wt (1 
μg) and different amounts (1; 2 and 6 μg, respectively) of F:p14ARF. Extracts were analyzed by WB with 
anti-Tat, anti-ARF and anti-actin, serum as indicated. (B) Total RNA from the same transfected cells was 
prepared and Tat mRNA levels were quantified using qPCR (C) Expression level of Tatwt are affected by 
the proteasome inhibitor MG132. H358-p14ARF inducible cell line were treated for 72 h in presence (+) 
or in absence (-) of Dox, then the cells were transfected with Tat-101 wt (2 μg) and 24 h post-
transfections, the cells were treated with 20 μM MG132 for 2 hr. Protein extracts were analyzed by WB 
with anti-Tat, anti-ARF and anti-actin antibodies, as indicated. (D) p14ARF reduces expression levels of 
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Tat-101 wt, Tat-Ub and Tatk71R-Ub fusion proteins. H358-p14ARF cells were treated for 72 h in 
presence (+) or in absence (-) of Dox, then the cells were transfected with the indicated Tat vectors and 24 
hr post-transfection cell extracts were analyzed by WB with anti-Tat, anti-ARF and anti-actin antibodies, 
as indicated. 
 
3.3.3 p14ARF affects the stability of Tat  
Accordingly with previous studies, (Bres et al., 2003), in the absence of 
p14ARF, Tat protein is quite stable as the relative protein level is largely 
unaffected by MG132 treatment. 
To examine the stability of Tat in the presence or absence of p14ARF, I 
transfected H358 cells in the presence or absence of doxycycline (Dox) 
(Figure 35). The Tat protein was quite stable, consistent with previous 
measurements of stability. However, p14ARF expression decreased Tat 
half-life, and the presence of covalently attached Ub-chain results in a 
modest increase of degradation of Tat-Ub. Collectively, these findings 
suggest that p14ARF induces de-stabilization of Tat via an ubiquitin-
independent pathway. 
.  
Figura 35.  p14ARF affects the stability of Tat-wt and Tat-Ub fusion protein. (A) In H358-p14ARF 
cells the expression of p14ARF was carried out as described before, then the cells were transfected with 
Tat-101 wt or with pTatWt-Ub, as indicated. Twenty-four hours post-transfections, protein translation 
inhibition was achieved with addition of 80 μg/ml of CHX for 2–4–6 h, as indicated. Cellular extracts 
were analyzed by WB with anti-Tat and anti-actin antibodies. (B) The densitometric signals were 
normalized to actin as a loading control. A 100% value was arbitrarily assigned to the signal at zero time 
of treatment. The results shown in (B) are from three independent experiments. 
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3.3.4 ARF/Tat interaction 
Experiments of gel filtration chromatography and glycerol density gradient 
sedimentation carried out in my laboratory, have demonstrate that the 
p14ARF protein association in high-molecular mass complexes (Berwistle 
et al., 2004) was counteracted by concomitant expression of Tat. Extracts 
from Tat-expressing cells clearly indicated the  induction of a partial 
p14ARF redistribution in a low-molecular weight complex. The 
concomitant presence of both Tat and p14ARF in the same fractions 
prompted us to investigate a possible interaction between Tat and p14ARF 
proteins.  
To analyze the putative association between Tat and p14ARF, 293T cells 
were co-transfected with p14ARF and a Tat expression vector. As control, 
we also co-transfected p14ARF and Hdm2. After transfections cell extracts 
were subjected to IP with p14ARF antibody followed by immunoblotting 
with Tat, p14ARF and Hdm2, respectively (Figure 36). As expected, 
Hdm2 was found to associate with p14ARF. Albeit at a lower efficiency, 
the Tat protein was found in p14ARF-IP material, while p14ARF-IP from 
untransfected cells did not. However, only a small fraction of Tat was 
detected in the ARF CoIP, suggesting that only a relative small amounts of 
Tat interacts with ARF. In conclusion, Tat induces a redistribution of ARF 
in a lower molecular weight complex and Co-IP results suggest that Tat can 
interact with ARF in the same complex. 
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Figure 36: Tat and p14ARF interaction. 293T cells were co-transfected by calcium-phosphate method 
with Tat-101 wt (5 μg), F:p14ARF (5 μg) and CMV-Hdm2 (2 μg) in different combinations as indicated. 
Whole-cell extracts were immunoprecipitated with anti-ARF C-18 antibody (lanes 1–6), anti IgG 
antibody (lanes 7–9). Immuno-complexes were analyzed by WB with anti-Tat, anti-ARF and anti-HDM2 
antibodies as indicated. Twenty percent of inputs (lanes 1–3) were loaded. 
 
3.3.5 ARF does not inhibit Tat functions by sumoylation or by sub-
cellular re-localization  
It has been shown that ARF- induced sumoylation observed for some ARF-
interacting proteins as WRN helicase, Hdm2, E2F-1, HIF-1α, TBP-1, 
p120E4F, might be a mechanism for ARF action through a common 
modification of different binding proteins. 
There are no evidences that Tat is a bona-fide substrate for ARF 
sumoylation; in order to investigate if the overexpression of the CELO 
adenovirus protein, Gam1, which is known to block ARF-induced 
sumoylation, could have overt effect on the ability of ARF to repress Tat, I 
transfected 293T cells with G5-83HIV-Luc (100 ng), F:Tat-101 wt (10 ng), 
F:p14ARF (500 ng) and CELO Gam1(500 ng). Gam1 does not alter the 
p14ARF repression of Tat protein (Figure 37). 
    
Figure 37. The p14ARF sumoylation does not involved the ARF repression of Tat functions. 293T 
cells were cotransfected with G5-83HIV-Luc (100 ng), F:Tat-101 wt (10 ng), F:p14ARF (500 ng) and 
CELO Gam1(500 ng).  p14ARF expression down regulates F:Tat101-wt and concomitant expression of 
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CELO Gam1 does not alter the p14ARF repression of Tat protein. Each histogram bar represents the 
mean of three independent transfections made in duplicate. 
 
Several studies have shown that ARF induces nucleolar re-localization of 
some of its binding partners. In order to test this hypothesis I transfected 
H358-ARF cells with GFP-Tat (2μg) and I treated with Dox (1 μg/ml) that 
induces the ARF expression  
As shown in Figure 38 by immunofluorescence assay I did not observe any 
significant difference in Tat sub-cellular localization upon ARF 
overexpression. Endogenus ARF protein presents as expected nucleolar 
sub-cellular localization and GFP-Tat has mostly nuclear localization. 
ARF overexpression does not change Tat original localization.  
A 
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Figure 38. The ARF expression does not alter the Tat localization . Immunofluorescence assay carried 
out in H358-ARF cells. The cells were transfected with GFP-Tat (2μg) and treated with Dox (1 
μg/ml).(A) The nucleolar p14ARF localization. (B) The localization of GFP-Tat. (C)  ARF does not 
change Tat original localization when co-expressed. 
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CHAPTER IV  
Discussion 
4.1 P-TEFb regulates positively c-Myc mediated- transcription 
The prevailing model of Myc-mediated transcription postulates that Myc 
increases local histone acetylation at promoters. Myc binds to histone 
acetyltransferase complexes including TRAAP 
(transformation/transcription –domain –associated protein) and either 
general control of amino-acid-synthesis protein-5 (GCN5) or TIP60, which 
preferentially acetylate histones H3 or H4, respectively (McMahon et al., 
1998; McMahon et al., 2000; Frank et al., 2001). Activation of Myc target 
genes in some cell systems occurs independently of an increase in histone 
acetylation (Eberhardy et al., 2000). Some Myc target genes are activated 
completely independently of TRRAP. Deletion of MBII inhibits Myc 
binding to TRRAP and dramatically reduces transcription, but some genes 
can still be activated in response to MycΔMBII (Nikiforov et al., 2000).  
Previous works have shown that Myc interacts with CycT1, the regulatory 
component of the P-TEFb complex (Eberhardy and Farnham 2001; 
Eberhardy and Farnham 2002; Kanazawa et al., 2003), a pivotal 
transcription factor that regulates elongation phase of transcription of RNA 
Pol II genes.  
However, the contributory role of P-TEFb in Myc transactivation remained 
elusive. In my work I have demonstrated that the Myc/Max heterodimer 
binds to P-TEFb. Co-IP assays indicate that the Myc/Max heterodimer 
copurifies with CycT1/CDK9 proteins and the absence of HEXIM1 in the 
Myc IP-associated proteins, suggests that Myc forms a complex 
exclusively with the core catalytic active P-TEFb complex.  
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ChIPs assays clearly have demonstrated that Myc induction directly 
recruits P-TEFb to chromatin templates, because I have found co-
occupancy of both factors (P-TEFb and the Myc/Max complex) at the E-
boxes of CAD and NUC  responsive genes.  
To analyze the involvement of the CDK9 kinase in transcriptional 
regulation drived by Myc, I used 5.6-di-chloro-1-b-D-ribofuranosyl-
bensimidazole (DRB), the pharmacological specific inhibitor of CDK9 
kinase activity. Analysis of cell cycle distribution of Rat-MycER cells in 
the presence of DRB treatments has shown strongly reduction of both 
Myc-induced proliferation and apoptosis. These results suggested that 
CDK9 is crucial for the induction of Myc-responsive gene as well as for 
Myc-induced cellular outcomes. Moreover, I also evaluated the relative 
levels of expression of two Myc-responsive target genes, nucleolin (NUC) 
and CAD and I have found that DRB specifically inhibits the expression of 
Myc-target genes at the concentrations that marginally affect the expression 
of housekeeping control genes. 
ChIPs analysis whit DRB treatment have demonstrated that kinases, likely 
CDK9, are required to phosphorylate Ser2-CTD of RNAPII when 
transiting at both NUC and CAD loci. DRB treatment during Myc 
activation did not alter the co-occupancy of both Myc and P-TEFb at the E-
box promoter region, while a strong inhibition of Ser2-CTD was seen in the 
coding region of both Myc target genes. Conversely, DRB treatment did 
not change Ser-5 CTD phosphorylation by TFIIH at the E-box, thus 
phosphorylation of Ser-2 CTD by CDK9 kinase appeared to represent an 
important limiting step for transcription of Myc-target genes.  
However, the contribution of other kinases to the inhibition of Myc-
responsive genes cannot be strictly excluded. High levels of Myc have been 
shown to strongly stimulate genome-wide RNAPII Ser-2 and Ser-5 
phosphorylation, and enhance mRNA cap methylation on target mRNAs, 
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even in the absence of the Myc DNA-binding domain. It has been shown 
that c-Myc can also bind to CDK7. These data highlight the strong 
interaction between Myc and CTD kinases and their effect on growth 
proliferation (Cowling and Cole 2007). 
P-TEFb is a multi-tasking complex (Brès et al., 2008) because influences 
multiple steps in gene expression, from transcription elongation and co-
transcriptional control of mRNA processing (splicing) and export through 
the CTD (Brès et al., 2005; Yoh et al., 2007), to mRNA translation in the 
cytoplasm (Rother et el., 2007). 
Recently, it has been shown (Zippo et al., 2007) that c-Myc binds the Pim1 
kinase through the MBII domain and recruits Pim1 to direct H3S10P at a 
site upstream of the c-FosL1 and ID2 target genes. Phosphorylation of 
H3S10 by JIL-1 kinase has been reported to be in Drosophila a prerequisite 
for recruitment of P-TEFb to heat shock genes (Ivaldi et al., 2007). 
Depletion of Pim1 blocks transcription as well as CTD Ser2P at c-FosL1 
and ID2 genes (Zippo et al., 2007). Thus, H3S10P seems to be a necessary 
step for P-TEFb loading (Figure 39).  
 
Figure 39. Transcription factors implicated in P-TEFb recruitment and function. Activators may 
recruit P-TEFb directly as c-Myc, or indirectly through binding to Brd4. P-TEFb recruitment is also 
linked to H3S10P, which can be mediated by  Pim1, which can be recruited through c-Myc:TRRAP 
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complexes. TRRAP is a frequent target of DNA activators and associates with HAT complexes that 
acetylate chromatin and stabilize binding of Brd4. P-TEFb functionally cooperates with proteins like 
SKIP to activate transcription and RNAPII CTD phosphorylation links elongation with downstream 
events required for gene expression. 
 
Collectively these studies together with the demonstration of P-TEFb / 
histone H2A:2B association in yeast (Wyce et al., 2007), propose the 
possibility that P-TEFb might influence nucleosome assembly or chromatin 
structure during elongation. 
c-Myc also associates with highly modified chromatin and is linked to H3 
acetylation and H3K4me3 and H3K79me3 (Guccione et al., 2006). 
Then, these data strongly indicate that Myc transactivation involves 
additional mechanisms that influence the structure and dynamic of the 
elongating polymerase without to exclude mechanisms that involve 
modulation of the chromatin context surrounding the Myc-responsive 
genes.  
4.2 p14ARF negatively regulates c- and N-Myc mediated 
transcriptional control 
Myc is the first oncogene identified to regulate ARF tumor suppressor 
functions. Overexpression of Myc in B-lymphocytes augments cell 
proliferation which is counteracted by the ARF-p53-Mdm2 axis. Inhibition 
of this axis suppresses Myc-induced apoptosis and facilitates B cell 
lymphoma formation. These findings indicate that Myc-induced cell 
growth and proliferation is balanced by simultaneous activation of p53 via 
ARF. However, several groups have argued that ARF functions 
independently of p53 in physically binding to E2F1 and MYC and 
attenuating their transcriptional activity (Eymin et al., 2001; Qi et al., 2004; 
Datta et al., 2004). In both wild type and p53-null MEFs in which MYC 
expression was enforced, MYC binding re-localized ARF from the 
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nucleolus to the nucleoplasm, whereas in other cell types (U2OS cells) 
ARF was found to import MYC into nucleoli (Qi et al., 2004; Datta et al., 
2004). However, more striking were observations that p19ARF could 
associate with MYC on chromatin, antagonizing the transactivation of 
selected MYC target genes as, eIF4E, nucleolin, TERT, Cdk4 and Cul1, 
without impairing Myc transrepression of of GADD45 and INK4B genes 
(Gregory et al., 2005). 
p19ARF and p14ARF show limited sequence homology at the levels of 
both  cDNA and protein. p19ARF is a protein of 169 a.a., while p14ARF of 
132 a.a. p19ARF is induced during Ras-mediated senescence, while 
p14ARF is not.  
These differences indicate that the data observed between p19ARF and 
Myc need to be experimentally validated for p14ARF. 
The data that I have obtained, have demonstrated that the human p14ARF 
interacts with c-Myc: through in vitro pull down assays and with in vivo 
CoIP, I have also shown that the Myc Box II domain is critical for the 
interaction with p14ARF. 
Moreover, I have demonstrated that another member of Myc family, N-
Myc, is able to bind p14ARF and the Myc Box III is the domain through 
which N-Myc contacts p14ARF.  
Although c-Myc and N-Myc share a high degree of functional redundancy, 
they have strikingly distinct patterns of gene expression. Whereas c-Myc is 
expressed during embryonic development and in adult tissues, N-Myc is 
expressed almost exclusively in embryonic tissues. 
It is pertinent to note that my studies demonstrate that c-Myc and N-Myc 
interact with p14ARF through different conserved domains. The Myc Box 
II and the Myc Box III are indispensable for many aspects of Myc 
functions among which also their transcriptional activity (Frank et al., 2003 
and Herbst et al., 2005). The immunofluorescence data obtained also 
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underlie and give relevance to the involvement of MBII and MBIII 
domains in the physiological interaction between ARF and Myc proteins. 
Moreover I have demonstrated that p14ARF inhibits c- and N-Myc 
transcriptional activation. 
There are several ways that p14ARF binding to Myc might inhibit its 
transactivating functions. One mechanism might involve ARF-induced 
sumoylation of Myc containing complexes or of neighboring histones 
(Shiio et al., 2003). As show in Figure 40A another potential mode of 
regulation might be mediated by ARF-BP1 (also known as HECTH9), a 
HECT containing E3 ubiquitin ligase with which ARF directly interacts 
(Chen et al., 2005). ARF-BP1 catalyses the lysine-63-linked 
polyubiquitylation of Myc, a process that facilitates the recruitment of co-
activators and the upregulation of Myc target genes (Adhikary et al., 2005). 
By contrast, the Myc transrepressing cofactor Miz1 antagonizes this 
modification (Figure 40B). ARF strongly inhibits the ubiquitin ligase 
activity of ARF-BP1, which might contribute to the selective dampening of 
Myc transactivating activity by ARF.  
Gels retardation experiments have excluded the hypothesis that the 
dampening effects of p19ARF on Myc-regulated transcription may result 
from interference with Myc binding to its heterodimerization partner Max, 
or from interference with Myc/Max heterodimer binding to E-box. 
Moreover in the laboratory it has been demonstrated that p14ARF does not 
possess an intrinsic repression domain. 
Then ARF might inhibit Myc’s functions interfering with the binding to co-
factors as the histone acetyl transferase TIP60 or P-TEFb (Figure 40C). A 
large number of evidences have demonstrated that Myc Box II is required 
for activation and repression of most target genes (Adnikary et al., 2005) 
and in addition to ARF, other proteins can bind directly to this region: the 
TRRAP, a core subunit of the TIP60 and GCN5 histone acetyltransferase 
 74
Discussion 
complex (HAT) (McMahon et al., 1998) and the ATPases TIP48 and TIP49 
found in chromatin remodelling complexes (Frank et al., 2001). 
 
  
c
Figure 40. Putative molecular mechanisms by which ARF might repress Myc activity. (A) The   
Myc–Max heterodimer binds to E-box (CACGTG) consensus sequences to activate transcription. 
Activation depends on the recruitment of cofactors such as TRRAP, TIP60 and on Myc ubiquitylation 
(Ub) by ARF-BP1. (B) Myc–Max complexes can also repress transcription by interacting at initiating 
elements (Inr) with the zinc-finger protein Miz1. Among its activities, Miz1 opposes the activity of ARF-
BP1. (C) Transcriptional activation and antagonism both depend upon Myc binding to CACGTG 
elements, thereby affecting a subset of Myc target genes, which include EIF4E (shown), nucleolin, 
telomerase reverse transcriptase, cyclin-dependent kinase 4 and cullin 1.   
 
4.3 p14ARF antagonizes HIV-1 Tat protein functions 
 
Another line of research in the laboratory investigates since several years 
mechanisms that involved the transcription activation of HIV-1 proviral 
DNA by RNAPII. This mechamisms are controlled primarily at the level of 
transcription elongation by the viral Tat protein (Barboric and Peterlin 
2005). The P-TEFb elongation complex was originally identified as a direct 
binding partner of the HIV-1 Tat protein, and Tat and Cyc T1 cooperate to 
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recruit P-TEFb to the viral 5’ TAR RNA (Price 2000; Saunders et al., 
2006).  
Moreover recently it has been demonstrated that ARF is a unexpected  
sensor of the viral infections, and in regard to this considerations I have 
supposed whether ARF could be able to negatively interfere with HIV-1 
Tat- mediated transcription. 
The tumor suppressor p14ARF, by antagonizing the E3 ubiquitin ligase 
Hdm2 activity, is known to inhibit cell-cycle progression and to stabilize 
p53 transcriptional activity. The proto-oncoprotein Hdm2 is also known to 
interact with HIV-1 Tat protein and mediates its ubiquitination in vivo and 
in vitro (Bres et al., 2003). Hdm2 is a positive regulator of Tat-mediated 
transactivation, indicating that the transcriptional properties of Tat are 
stimulated by ubiquitination (post-translate modification).  
Since Hdm2 is negatively regulated by p14ARF, I wished to determine 
whether p14ARF could affect Tat transactivation of the HIV-1 promoter 
interfering with Hdm2-mediated ubiquitination of Tat. 
The data I have obtained demonstrated that p14ARF enhanced expression 
inhibits Tat transactivation of the HIV-1 LTR promoter in transient 
transfections and that the N-terminus of p14ARF is required for ARF-
mediated inhibition. I observed such effects in different cell lines that 
express or do not express the p53 factor, suggesting that the repression of 
Tat transactivation is p53-independent.  
Moreover I have demonstrated that HIV-1 Tat protein levels are reduced in 
the presence of p14ARF in a proteasome-dependent manner and the 
induction of degradation is independent on the ubiquitin state of the Tat 
protein. Tat protein is quite stable and co-expression of p14ARF induces 
Tat protein half-life decrease.  
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Furthermore it has been shown in the laboratory that Tat induces a 
redistribution of ARF in a lower molecular weight complex, and that Tat 
can interact with ARF in the same complex. 
ARF-mediated repression of Tat protein could occur by sumoylation 
mechanism. It has been shown that ARF-induced sumoylation for some 
ARF-interacting proteins as WRN helicase, Hdm2, E2F-1, HIF-1a TBP-1, 
p120E4F (Rizos et al., 2005; Tago et al., 2005). I have carried out other 
experiments that indicate to exclude this hypothesis because 
overexpression of Gam1 vector, which blocks ARF-induced sumoylation, 
had no overt effect on the ability of ARF to repress Tat. 
Another mechanism by which p14ARF could counteract HIV-1 Tat protein 
functions could involve a change in Tat sub-cellular localization. Several 
studies in fact have shown that ARF induces nucleolar re-localization of 
some of its binding partners, but in my findings I did not observe any 
significant difference in Tat sub-cellular localization upon p14ARF 
overexpression. 
Recent studies have shown that p14ARF induces proteasomal degradation 
in both p53-dependent and independent manner (Eymin et al., 2006; Rizos 
et al., 2007). My data clearly indicate that ARF is capable of inducing a 
proteasome-dependent degradation of Tat protein.  
The first evidence of a link between ARF and the proteasome was the 
observation that both human and mouse ARF were accumulated following 
treatment with proteasome inhibitors, suggesting that ARF degradation 
depends, at least in part, by the proteasome (Kuo et al., 2004).  
A very recent report describes a direct involvement of the REG-γ 
proteasome in an ubiquitin-independent regulation of the ARF turnover 
(Chen et al., 2007; Li et al., 2007).  
REG-γ pathway plays a role in the control of viral pathogenesis and this is 
particularly interesting, given that ARF activation has been linked to viral 
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response (Garcia et al., 2006). Interestingly, both ARF and Tat physically 
interact with REG-γ complex, (Huang et al., 2002), also known as 11S or 
PA28. Then it is possible that functional interaction between 
ARF/Tat/REGγ might be responsible for p14ARF- induced degradation of 
Tat protein. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Material and Methods 
CHAPTER V  
Material and Methods 
5.1 Plasmids  
pcDNA3-Myc and pcDNA3-CycT1 plasmids were already available in lab. 
G5-83HIV-Luc and Tat-101 wt plasmids were already available in lab. The 
insert obtained by GFP-p14ARF was subcloned in pPROEX Hta vector 
(GIBCO Life Technologies) to give the pHis-ARF vector.  
GFP-p14ARF, GST-p14ARF, GST-Max, His-Max, pcDNA3-Max, pHA-
Myc-FLAG, pcDNA3-FLAG-Myc, pcDNA3-FLAG-MycΔ123-151, 
pMT2T-Myc, pcDNA-p14ARF-HA, GST-Myc deletion mutants, pMT2T-
Myc, hTERT-Luc were kindly provided by G. La Mantia and R. Dalla 
Favera. 
p3xFLAG-N-Myc was kindly provided by G. Della Valle. pcDNA-N-Myc 
and his deletion mutant were kindly provided by T. Fotsis. 
p3xFLAG-ARF F.L., p3xFLAG-ARF1-65 and p3xFLAG-ARF65-132 were 
constructed by inserting EcoRI/BglII fragment, obtained by PCR reaction and 
containing the ARF cDNA (full length, aa 1-65 and aa 65-132, respectively), 
in pCMV10 vector (Sigma). PCR reactions: the cDNA were performed with 
PFU TURBO DNA Polymerase (Stratagene).  
pTat-Ub and pTatK71R-Ub plasmids were kindly provided by M. Benkirane. 
5.2 Cell lines and treatments 
Rat cells expressing a 4-hydroxytamoxifen (OHT)-inducible MycER 
chimera were cultured in DMEM medium supplemented with 10% fetal 
calf serum. Cells were made quiescent by contact inhibition followed by 
serum removal for two days. To induce entry into the cell cycle, the 
synchronized G1 arrested cells were treated with 4-OHT (600 nM) and 
harvested at the indicated times. Human 293T, SKNBE, U2OS, HL6, 
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H1299 cell lines were grown in DMEM supplemented with 10% fetal calf 
serum. Human H358/Tet-On/p14ARF inducible cell line (kindly provided 
by Dr. M. S. Gazzeri) was cultured in RPMI 1640 medium supplemented 
with 10% foetal bovine serum. H358-p14ARF inducible cell line was 
treated for 72 h with o without 1 μg/ml doxycycline (Dox), then the cells 
were transfected with Lipofectamine (Invitrogen) and 24 h posttransfection, 
cells were treated with 80 μg/ml of cycloheximide (CX; Sigma) and 
harvested at the indicated times thereafter. Proteasome inhibition was 
achieved by treating the cells with 20 μM MG132 for 2 hr. 
 
5.3 Luciferase assays and immunofluorescence 
For the luciferase assay, the cells were transfected with lipofectamine or 
lipofectamine 2000 (Invitrogen Technologies) and pRLCMV (Promega) 
was co-transfected for normalization.  
After 48 hrs from transfection the cells were lysed and assayed for activity 
of firefly or Renilla luciferase by measure with the dual luciferase assay kit 
(Promega) according to the manufacturer’s instructions and using a T20/20 
luminometer (Turner Design). Plasmids used in transient transfections: 
hTERT-Luc, pMT2T-Myc, pcDNA-p14ARF-HA, G5-83HIV-Luc vector 
containing the HIV-1 LTR sequences from -83 to +85, Tat-101 wt, 
F:p14ARF, F:p14ARF(1–65), F:p14ARF (65–132), pTatWt-Ub and 
pTatk71R-Ub, and pCMVHdm2.  
For immunofluorescence analysis U2OS and SKNBE cells were 
transfected with lipofectamine 2000 with 200ng of the pcDNA3-FLAG-
Myc, pcDNA3-FLAG-MycΔ123-151, GFP-ARF, pcDNA-N-Myc and 
pcDNA-N-MycΔ1-300 plasmids and the cells processed as described in 
Napolitano et al., 2003 using anti-Myc (9E10, Santa Cruz Biotechnology, 
Inc.) antibody. 
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5.4 In vitro proteins binding assays 
BL21 bacterial cells were transformed with prokaryotic expression vector 
carrying the cDNA of the protein of our interest.  
Bacterial cells were lysed in PBS 1X Buffer with 1mM PMSF and protease 
inhibitors and subsequently sonicated. The lysates were centrifuged and 
recombinant proteins were affinity purified: the GST-fusions (GST; GST-
ARF; GST-Max; GST-Myc 1-42; GST-Myc 1-103; GST-Myc 1-143; GST-
Myc 1-228; GST-Myc 151- 340; GST-Myc 262-349) were purified using 
glutathione-sepharose (Amersham Biosciences) and subsequently eluted 
from the beads by 20mM glutathione incubation. His-Max and His-ARF 
proteins were affinity purified by using Ni-NTA Agarose (Invitrogen life 
technologies) and subsequently eluted in Buffer C (20mM Tris-HCl; 
100mM KCl; 5mM 2-mercaptoethanol, 10% glycerol, 100mM imidazole). 
The HA-Myc-FLAG protein was double purified in two steps. For the 
individual experiments 600ng of each recombinant protein were incubated 
in a final volume of 1 ml of Binding Buffer (50mM Tris-HCl pH7,4; 150-
500mM NaCl; 1mM MgCl2; 1mM DTT; 0,2% NP40). After extensive 
washing in Binding Buffer, the bound proteins were eluted by 2X Laemli 
buffer, separated on SDS PAGE followed by Western Blotting. 
5.5 Antibodies and co-immunoprecipitations  
The following antibodies were used for the immunological techniques: 
anti-Myc (N262 for IP and 9E10 for WB, Santa Cruz Biotechnology), anti-
Max (C17, Santa Cruz Biotechnology), anti-ARF (C-18, Santa Cruz 
Biotechnology), anti-FLAG M2 Monoclonal Antibody-Peroxidase 
Conjugate (Sigma), anti-GST (B-14, Santa Cruz Biotechnology), 6xHis 
Monoclonal Antibody (BD Biosciences), anti-GST (B-14, Santa Cruz 
Biotechnology), anti N-Myc (2,Santa Cruz Biotechnology), anti CycT1 
(H245 for immunoprecipitation, C-20, T18 and N19 for WB, Santa Cruz 
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Biotechnology), anti-HEXIM1, and anti-CDK9 (H-169), anti-actin (I-19, 
Santa Cruz Biotechnology), anti-HDM2 (Calbiochem) and HIV-1 Tat 
Antiserum (NIH AIDS Research). 
Co-immunoprecipitations from transiently transfected cells were so carried: 
each mg of protein extract was incubated O.N. at 4°C with 2-5 μg of 
specific antibody for the protein of interest. The day after, the antibodies 
were immunoprecipitated by incubating the supernatants with protein G 
Sepharose 4 fast flow for 2 h at 4°C. The beads were washed 5 times for 5 
min each at 4°C using buffer F (10mM Tris-HCl pH7.5, 150mM NaCl, 
30mM Na4O7P2, 50mM NaF, 5μM ZnCl2, 0.1mM Na3VO4, 1% Triton, 
0.1mM PMSF) before loading on SDS-PAGE. 
5.6 FACS analysis 
Rat1-Myc-ER cells were trypsinised, collected by centrifugation and 
washed in phosphate-buffered saline (PBS). Cells were resuspended in 
hypotonic solution 0.1% Na-Citrate, 50 g/ml propidium iodide, 6.25 g/ml 
RNAse, and 0.00125% Nonidet P40 (Sigma Chemical Co), incubated in 
absence of light for 30-60 at room temperature. Cell cycle data acquisition 
and analyses were performed on a Becton Dickinson flow cytometer using 
CellQuest Pro and ModFit 3.0 software. 
5.7 mRNA measurement by quantitative Real-Time PCR 
Total RNA was isolated from cells using TRIZOL reagent according to the 
manufacturer’s instructions (Invitrogen). The RNAs were treated with 
Dnase I (Invitrogen) and 2 µg of total RNA was reverse transcribed with 
100U Super Script II Rnase H- Reverse Transcriptase (Invitrogen) in a 
volume of 40 µl, using 100 µM random hexamer primers (Roche) 
according to the manufacturer’s instructions (Invitrogen). cDNA was 
diluted 1:3 prior use in quantitative PCR (qPCR). Quantitative analysis was 
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performed by using the AbiPrism 7500 sequence detector system (Perkin-
Elmer Applied Biosystems). The PCR reactions were performed in a final 
volume of 15 µl using 1 µl of cDNA, 5 pmol of each primer and 7.5 µl of 
SYBR GREEN 2× PCR Master Mix (Applied Biosystems). Each sample 
was run in triplicate. PCR cycling profile consisted in 50°C for 2 min, 95°C 
for 10 min and 40 two-step cycles at 95°C for 15 s and at 60°C for 1 min. 
Quantitative real time PCR analysis was carried out using the 2(-Delta 
Delta C(T)) method (2-Ct) (Livak and Schmittgen 2001). In all qPCR 
experiments the data were normalized to the expression of housekeeping 
beta-glucuronidase (GUS) and 18S RNA genes.  
5.8 ChIP-re-ChIP analysis 
Rat-MycER cells were serum starved for two days and treated with 4-OHT 
for the indicated hrs. After PBS wash, cells were cross-linked with a 1% 
formaldehyde/PBS solution for 10 min at room temperature. Cross-linking 
was stopped by adding glycine and incubating for 5 min at room 
temperature on a rocking platform. The medium was removed and the cells 
were washed twice with ice-cold phosphate-buffered saline (PBS) (140 
mM NaCl, 2.7 mM KCl, 1.5 mM KH2PO4 and 8.1 mM Na2HPO4.2H2O). 
The cells were collected by scraping in ice-cold PBS supplemented with a 
protease inhibitor cocktail (Sigma). After centrifugation the cell pellets 
were resuspended in lyses buffer [1% SDS, 10 mM EDTA, protease 
inhibitors and 50 mM Tris–HCl (pH 8.1)] and the lysates were sonicated to 
result in DNA fragments of 300 to 600 bp in length. Cellular debris was 
removed by centrifugation and the lysates were diluted 1:10 in ChIP 
dilution buffer [0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM 
NaCl, protease inhibitors and 16.7 mM Tris–HCl (pH 8.1)]. Non-specific 
background was removed by incubating the chromatin resuspension with a 
salmon sperm DNA/protein A-agarose slurry (Upstate Biotechnology, Lake 
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Placid, NY, USA) for 5 h at 4 C with agitation. The samples were 
centrifuged and the recovered chromatin solutions were incubated with 8 
g of indicated antibodies overnight at 4 C with rotation. The antibodies 
against c-Myc (N262), CycT1 (T18, T20 and H245) were obtained from 
Santa Cruz Biotechnologies. The immuno-complexes were collected with 
60 l of protein A-agarose slurry (Upstate Biotechnology) for 1 h at 4 C 
with rotation. The beads were pelleted by centrifugation at 4 C and washed 
sequentially for 5 min by rotation with 1 ml of the following buffers: low 
salt wash buffer [0.1% SDS, 1% Triton X-100, 2 mM EDTA, 150 mM 
NaCl and 20 mM Tris–HCl (pH 8.1)], high salt wash buffer [0.1% SDS, 
1% Triton X-100, 2 mM EDTA, 500 mM NaCl and 20 mM Tris–HCl (pH 
8.1)] and LiCl wash buffer [0.25 mM LiCl, 1% Nonidet P-40, 1% sodium 
deoxycholate, 1 mM EDTA and 10 mM Tris–HCl (pH 8.1)]. Finally, the 
beads were washed twice with 1 ml TE buffer [1 mM EDTA and 10 mM 
Tris–HCl (pH 8.0)]. For re-ChIP the immunocomplexes were eluted by 
adding 100 l re-ChIP elution buffer (10 mM DTT) at room temperature 
for 30 min with rotation, the supernatant was diluted 1:20 in ChIP dilution 
buffer and the antibody against the second protein of interest was added, 
the new immuno-complexes were allowed to form by incubating at 4°C 
overnight on a rocking platform, the immuno-complexes were collected by 
incubating with 60 l protein A-agarose slurry at 4 C for 1 h on a rocking 
platform and finally washed as indicated above. In both cases the immuno-
complexes were then eluted by adding 500 l elution buffer (1% SDS and 
100mM NaHCO3) and incubation for 15 min at room temperature with 
rotation. After centrifugation, the supernatant was collected and the cross-
linking was reversed by adding NaCl to final concentration of 200 mM and 
incubating overnight at 65°C. The remaining proteins were digested by 
adding proteinase K (final concentration 40 g/ml) and incubation for 2 h 
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at 55 C. The DNA was recovered by phenol/chloroform/isoamyl alcohol 
(25/24/1) extractions and precipitated with 0.1 volumes of 3 M sodium 
acetate (pH 5.2) and 2 vol of ethanol using glycogen as a carrier. 
Immunoprecipitated DNA was analyzed by PCR using sets of primers 
against regions of NUC encompassing E-Box (+574) and coding region 
(+1500) and CAD E-Box and coding region (+3258). The ACHR promoter 
ampicon was used as negative control in all experiments. PCR products 
were analyzed by semiquantitative and quantitative Real-Time PCR.
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